(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property Organization International Bureau
(43) International Publication Date PCT (10) International Publication Number 9 July 2009 (09.07.2009) WO 2009/085562 Al
(51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07C 235/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, (21) International Application Number: CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, PCT/US2008/085716 EG, ES, FT, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (22) International Filing Date: LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, 5 December 2008 (05.12.2008) MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 61/016,783 26 December 2007 (26.12.2007) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, (71) Applicant (for all designated States except US): LEAD FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, THERAPEUTICS, INC. [US/US]; 999 Bayhill Drive, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, Suite 130, San Bruno, California 94066 (US). CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: (72) Inventors; and — as to applicant's entitlement to applyfor and be granted a (75) Inventors/Applicants (for US only): CHU, Daniel patent (Rule 4.17(U)) [US/US]; 3767 Benton Street, Santa Clara, California — as to the applicant's entitlement to claim the priority of the 95051 (US). YE, Tao; Flat D 11th Floor, Block 5 Lily earlier application (Rule 4.17(Ui)) Mensions, Sit 9, Whampoa Garden Hung Horn, Kowloon (HK). Published: — with international search report (74) Agents: WILSON SONSINI GOODRICH & ROSATI — before the expiration of the time limit for amending the et al; 650 Page Mill Road, Palo Alto, California 94304- claims and to be republished in the event of receipt of 1050 (US). amendments
(54) Title: NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS
(57) Abstract: Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopep- tides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Com- pound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate or carrying a Hofmann degradation of the primary amide of the 3rd amino acid as- paragines with phenyl-bis-trifluoroacetate to give the primary amine. Also provided are methods for the synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections. NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Patent Application No 61/016,783 filed December 26, 2007, the contents of which are incorporated by reference in its entirety. FIELD OF THE INVENTION
[0002] Described herein are semi-synthetic glycopeptides having antibacterial activity, pharmaceutical compositions comprising these compounds, and methods of treatment using semi-synthetic glycopeptides. BACKGROUND OF THE INVENTION
[0003] The emergence of drug resistant bacterial strains has highlighted the need for synthesizing and identifying antibiotics with improved activity Naturally occurring and semi-synthetic glycopeptide antibiotics used to combat bacterial infections include compounds such as vancomycin, desmethylvancomycin, eremomycm, teicoplanin (complex of five compounds), dalbavancin, oritavancin, telavancin, and A82846B (LY264826) having structures A, B, C, D, E, F, G and H:
R = B-2.Acetylam Ido-s lucopyranoβyl-
D [0004] These compounds are used to treat and prevent bacterial infection, but as with other antibacterial agents, bacterial strains having resistance or insufficient susceptibility to these compounds have been identified, and these compounds have been found to have limited effect against certain bacterial infections e.g., against pulmonary S. aureus infections caused by Compound A intermediate-resistant S. aureus or infections due to Compound A rcsistant-enterococci. SUMMARY OF THE DWENTION [0005] Described herein are semi-synthetic glycopeptides that have antibacterial activity. Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.
[0006] In one aspect described herein are compounds formed by modification of Compound A, Compound B, Compound C or Compound H scaffolds to provide semi-synthetic glycopeptides that have antibacterial activity, as well as their pharmaceutical acceptable salts, esters, solvates, alkylated quaternary ammonium salts, stereoisomers, tautomers or prodrugs thereof, and which are used, in some embodiments, as antibacterial agents for the treatment of bacterial infections with superior microbiology and pharmacokinetic properties than currently available glycopeptide antibacterial agents.
[0007] In one aspect described herein are compounds having a structure selected from the group consisting of Formulas [I XIl): wherein,
R A is selected from the group consisting of a) hydrogen,
b) methyl,
c) C2-Ci 2-alkyl; Ri and R are each independently selected from the group consisting of
a) hydrogen,
b) C 1-C 12-SIkYl,
c) Cj-Ci 2-alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen,
(b) hydroxy,
(c) C r Ci r alkoxy,
(d) Ci-C 3-alkoxy- Cj-Cralkoxy, (e) amino,
(g) Ci-Ci 2-dtalkylamino, (h) alkeayl,
(i) alkynyl, (j) C C -thioalkoxy,
Cr C]2-alkyl substituted with aryl,
) Ci-C]2-alkyl substituted with substituted aryl, f ) C]-Cl2-aikyl substituted with heteroaiyl, g) Ci-Ci2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkcnyl, j) heterocycloalkyl, or
Ri and R2 taken together with the atom to which they are attached form a substituted heteroaryl or 3-10 raembered heterocycloatkyl ring which optionally contains one to two
hetero functionalities selected from the group consisting of -O-, -N-, -N-, -NH, -N(C1-C -
alkyl)-, -N(aryi)-, -Nfaryl- Cr C -alkyl-)-, -N(substituted-aryl- Cr C -alkyl-)-, -
Nfheteroaryl)-, -N(heteroaryl- Cr C6-alkyl-)-, -N(substituted-heteroaryl- d-Q-alkyl-)-, and -S- or S(O) - wherein n is 1 or 2 and the 3- 10 membered heterocycloalkyl ring is
optionally substituted with one or more substtuents independently selected from the group consisting of
(a) halogen, (b) hydroxyl,
(c) Cr C3-alkoxy,
(d) Cr Cr alkoxy-Cr C3-aikoxys (e) oxo, (i) Ci-C,-alkyl,
(g) halo-C r C3-alkyl, (h) CrCa-alkoxy-CrCs-alkyl, and k) C(=O) R7,
1) C(=0) CH R8 R and R 1 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or
and R1 or R and R1 taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl πng which is optionally substituted with one or more substituents independently selected from the group consisting of
(a) halogen,
(b) hydroxyl,
(c) Cr C3-alkoxy,
(d) C,-C3-alkoxy-Ci-C3-alkoxy, (e) oxo, (f) Cr C3-alkyl, (g) halo-C.-Cj-alkyl,
(h) C1-C3-alkoxy-Ci-C 3-alkyl; is selected from the group consisting of
a) hydrogen,
b) Cr C[2-alkyl,
c) CrCi 2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen,
(b) hydroxy,
(c) Ci-C -alkoxy,
(d) C1-C3-aikoxy-C,-C r alkoxy, (e) amino,
(f) C C]2-allcy]aniino, (g) Ci-Ci2-dialkylamino,
(h) alkenyl,
(i) alkynyl,
Q) Ci-C -thioaUcoxy,
d) Ci-Ci2-alkyl substituted with aryl,
) Ci-Ci 2-alkyl substituted with substituted aryl,
f) Cj-C, 2-alkyl substituted with heteroaryl,
g) Ct-Ci 2-alkyl substituteNi with substituted heteroaryl, ) cycloalkyl, cycloalkenyl,
J) heterocycloalkyl, ) Q-C^-alkylamino; X is selected from the group consisting of (D hydrogen, (2) chlorine; Y is selected from the group consisting of
(1) oxygen, (2) NRi, wherein Rj is as previously defined; Z is selected from the group consisting of
(1) oxygen, (2) suliur;
R is selected from the group consisting of
(D hydrogen, (2) cycloalkyi,
(3) cycloalkenyl, (4) Ci-Ca-alkyl,
(5) Ci-C 12-alkyl substituted with one or more substituents selected from the group consisting of
(a) halogen, (b) hydroxy,
(C) C]-Ci2-aIkoxy,
(d) CpCj-alkoxy- C 1-C3-EtIkOXy,
(e) -COOR 5 wherein R5 is hydrogen or loweralkyl,
(Q -C(O)NR R wherein R5 is as previously defined and R6 is hydrogen or loweralkyl,
(g) amino,
(h) -NR 5R wherein R and R 5 are as previously defined, or
R5 and R are taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or
more substituents independently selected from the group consisting of
(i) halogen,
(ii) hydroxy,
(iii) C r C3-alkoxy, (iv) Cj-Cj-alkoxy-Ci-Cralkoxy,
(v) oxo,
(vi) d-C^-alkyl,
(vii) halo-Ci-Cu-alkyl,
and
(vύi) Ct-C r alkoxy-Ci-Ci2-alkyl 7 (i) aryl,
(j) substtuted aryl,
(k) heteroaryl,
(1) substituted heteroaryl,
(m) mercapto,
(n) C r Ci2-thioalkoxy,
(6) C(=0)0 Rn, wherein R 11 is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl,
(7) C(=0)N R ] R i2, wherein R 11is as previously defined and R ]2 is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl,
or
Rn and R i together with the atom to which they are attached form a 3-10 membered
heterocycloalkyl πng, which is optionally substituted with one or more substituents
independently selected from the group consisting of (a) halogen,
(b) hydroxy,
(c) C1-C3-alkoxy,
(d) C,-C -alkoxy-Ci-C 3-alkoxy,
(e) OXO, (0 d-Cs-alkyl (g) substituted loweralkyl,
(h) hafo-C r C 12-alkyl, (0 amino, 0) alkylamino, (k) dialkylamino and
(1) Ci-C 3-alkoxy-C,-C 12 -alkyI, or
R and its connected oxygen atom taken together is halogen;
R3 is selected from the group consisting of (1) OH,
(2) 1-adamantanamino,
(3) 2-adamantanainino,
(4) 3-amino-l-adamatitauiamino,
(5) l-amino-3-adamaritanariiino,
(6) 3-loweralkylamino-l-adamantananiino,
(7) l-loweralkylamino-3-adamantanamino,
(8) amino,
(9) NRi 3R]4 wherein R 13 and R 14 are each independently selected from the group consisting of hydrogen, loweralkyl, substituted loweralkyl, cycloalkyl, substituted cycbalkyl, aminoloweralkyl
wherein the amino portion of the aminoloweralkyl group is further substituted with unsubstituted or
substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy,
and substituted aryloxy
or
Ri3 and R 4 together with the atom to which they are attached form a 3-10 membercd heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the
group consisting of
(a) halogen,
(b) hydroxy,
(c) C,-C 3-aIkoxy, (d) CrCa-alkoxy-Cj-Cj-alkoxy, (e) oxo,
(f) CrCiralkyl, (g) substituted toweralkyl,
(h) halo-Ci-Ci2-alkyl, (i) amino,
Q) alkylamino,
(k) dialkylamino, and
(1) Cr C3-alkoxy-C1-Ci 2-a]kyl;
R4 s selected from the group consisting of (1) wherein m is 1to 6 and Ri is H or loweralkyl, CH 2NH-CHRIJ-(CH X11-NHSO 2RB,
(2) CH2NH- CHRu -(CH 2)P-CONHSO 2RB, wherein p is 0 to 6 and i5 is H or loweralkyl,
(3) CH2NH- CHR]5 -(CH2)p-C00H, wherein p is 0 to 6 and R] is H or loweralkyl,
(4) CH 2NRF-CHR 15-(CH 2V-NROSO 2RE!, wherein q is 2 to 4 and R 5 is H or loweralkyl, RF
and R are independently hydrogen, lower alky] or taken together represents a -CH2- , (5) H,
(6) CH2NHCH PO3H2, (7) aminoloweralkyl wherein the amino portion of the aminoloweralkyl group is further
substituted with unsubstituted or substituted alky], alkenyl, cycloalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy;
R B is selected from the group consisting of a) aryl,
b) Cr C12-alkyt, c) C|-Ci2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy,
(c) Ci-C 12-alkoxy,
(d) Ci-Cr alkoxy- Ct-Cr alkoxy, (e) amino,
(f) Ci-Ci2-alkykmino, (g) Ci-Cn-dialkylamino, (h) alkenyl,
(i) alkynyl, (j) Ci-Cij-thioalkoxy,
d) Ci-C ]2-alkyl substituted with aryl,
e) Cj-Ci2-alkyl substituted with substituted aryl, f) Ci-Cij-alkyl substituted with heteroaryl,
g) Ci-Ci 2-alkyl substituted with substituted heteroaryl, h) cycloalkyl,
i) heteroaryl, j) heterocyoloalkyl, k) aryl substituted with one or more substituents selected from the group consisting of
(a) halogen, (b) hydroxy,
(C) Cj-C]2-aIkoxy,
(d) CrC -aikoxy- Cr C6-alkoxy, (e) amino, (0 amino-CrCs-alkoxy,
(g) Ci-Ci 2-alkylamino,
(li) Ci-Ci 2-aliylaniino- Cr C«-alkoxy,
(1) C]-Cj2-dialkylan ώio,
0) Cj -C^-dialkylamino- CrC^-alkoxy, (k) alkenyl,
(1) alkynyl,
Cm) Cr Ci2-thioalkoxy,
(«0 d-Cu-alkyl,
1) hsteroaryl substituted with one or more substituents selected from the group consisting of (a) halogen,
0>) hydroxy,
) CrC -alkoxy- Cj-C -alkoxy, (e) amino, amino-Ci-C(-alkoxy,
(8) Ci-Ci 2-alkylamino, (h) Ci-C^-alkylamino- CpQ-alkoxy,
(i) Ci-C 12-dialkylamino, π 0) Ci-C^-dialkylami o- Cr C6-alkoxy,
O aJkenyl,
(i) alkynyl, (m) Ci-Cij-tbioalkoxy,
(n) CrC -alkyl;
hydrogen, b) C,-Ci2-alkyl,
Ci-C -alky] substituted with one or more substituents selected from the group consisting of
(a) halogen, (b) hydroxy,
(C) C,-Ci 2-alkoxy, ((J) Ci-Cr alkoxy- Cr C3-alkoxy, (e) amino, (f) CrC^-alkylamino,
(g) Ci-Ci2-dialkylaniino, (h) alkenyl, (i) alkynyl,
O) Ci-Cu-thioaUroxy, d) Ci-C -alkyl substituted with aryl,
e) Cr C]2-alkyl substituted with substituted aryl,
f ) Ci-C 12 -alkyl substituted with hetcroaryl, g) Ci-Cir lkyl substituted with substituted heteroaryl, h) cycloalkyl,
i) cycloalkenyl, j) heterocycloalkyl,
k) C(=O) R7 wherein R is previously defined,
1) R9 and R 0 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or
Ra and R or R9 and Rio taken together with the atom to which they are attached form a 3-
10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen,
(b) hydroxyl,
(c) C,-C3-alkoxy,
(d) Ci-C3-alkoxy-Cr C3-aIkoxy, (e) oxo,
(f) Cr Cr alkyl,
(g) halo-CrC r alkyl,
(h) CrC 3-alkoxy-Ci-C3-alkyl;
R and RE are each independently selected from the group consisting of a) hydrogen,
b) C,-Ci r alkyl, c ) Cr Ci2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen,
(b) hydroxy,
(c) Ci-Ci2-alkoxy,
(d) C]-C3-alkoxy, (β) amino,
(f) C r C 12-alkylamino,
(g) C[-Ci 2-dialkylamino, (h) alkenyl,
O) alkynyl,
O) Ci-Cu-tbioalknsty, d) Ci-C t2-alkyl substituted with aryl, e) Ci-C -alkyl substituted with substituted aryl, f) Cr Ci2-alkyl substituted with heteroaiyl, g) Cr Ci2-aIkyI substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j ) heterocycloalkyl,
or
RD and RE taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which optionally contains one to two hetero functionalities selected
from the group consisting of-O-, -N-, -NH, -N(Ci-C 6-alkyl)-, -Nfaryl)-, -N(aryl- C] C6-
alkyl-)-, -N(substituted-aryl- Cr C -alkyI-)-, -N(heteroaryl)-, -N(heteroaryl- C,-C -alkyl-)-, -N(substituted-heteroaryl- Ci-C -alkyl-)-, and -S- or S(O) - wherein n is 1 or 2 and the 3- 11 1 membered heterocycloalkyl ring is optionally substituted with one or more substituents
independently selected from the group consisting of
(a) halogen,
(b) hydroxyl,
(c) Cr C3-alkoxy,
(d) Ci-C 3-BIkOXy-Cj-C3-EJkOXy, (e) oxo,
(f) C -alkyl,
(g) halo-d-Cj-alkyl,
(h) Q-Cj-alkoxy-Ci-Cj-alkyl, and k) C(=O) R7 wherein R is previously defined,
1) C(=O) CH R8N R Ri0 wherein R8, R9 and Rifl are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl,
heteroaryl or substituted heteroaryl,
or
R8 and Ri0 or R9 and R 10 taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more
substituents independently selected from the group consisting of
(a) halogen, 0>) hydroxyl,
(C) Cr C3-alkoxy,
C Ci-C 3-OIkOXy-Ci-C3-BIkOXy, (e) oxo,
(O Ci-C 3-alkyl,
(g) halo-C r C -alkyl,
(h) C r Cralkoxy-Ci-C 3-alkyl,
m) C(=0) CH R NR R7 wherein R7, R8 and R are as previously defined; or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof,
[0008] In a further embodiment, the compound has the structure of Formula I
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R , etc. have the meanings as defined herein.
[0009] In a further embodiment, the compound has the structure of Formula II
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R, etc. have the meanings as defined herein.
[OOIO] In a further embodiment, the compound has the structure of Formula III or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R, etc. have the meanings as defined herein.
[001 1] In a further embodiment, the compound has the structure of Formula IV
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R, etc. have the meanings as defined herein.
[0012] In a further embodiment, the compound has the structure of Formula V
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R, etc. have the meanings as defined herein.
[OO13] In a further embodiment, the compound has the structure of Formula VI or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R, etc. have the meanings as defined herein.
[0014] In a further embodiment, the compound has the structure of Formula VH
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R, etc. have the meanings as defined herein,
[0015] In a further embodiment, the compound has the structure of Formula VIII
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R5etc. have the meanings as defined herein, [0016] In a further embodiment, the compound has the structure of Formula IX or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R5 etc, ve the meanings as defined herein. [0017] In a further embodiment, the compound haa the structure of Formula X
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings as defined herein.
[0018] In a further embodiment, the compound has the structure of Formula Xl
or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R, etc. have the meanings as defined herein.
[0019] In a further embodiment, the compound has the structure of Formula XII or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer,
tautomer or prodrug thereof, wherein R, etc. have the meanings as defined herein.
[0020] In a further embodiment of any of the above structures, RA is methyl and R is hydrogen, In embodiment, RA
is hydrogen and R4 is hydrogen. In another embodiment, X is hydrogen and R4 is hydrogen. In a further embodiment,
X is chlorine and R4 is hydrogen. In yet a further embodiment, RA is methyl and R4 is CH NHCH2PO H . In another
embodiment, RA is hydrogen and R4 is CH NHCH 2PO3H2. In one embodiment, RA is hydrogen and R4 is CH2NH-
CHR]5 (CH )nI-NHSO2RB, wherein m is 1 to 6 and R 5 is H or loweralkyl. In another embodiment, RA is hydrogen σ and R4 is CH2NRF-CHRis-(CH2)q-NR SO2RB, wherein q is 2 to 4, R15, RF and R is H or loweralkyl, RF and R together represents --CH2-. In yet another embodiment, RA is hydrogen and R is CH NH- CHR 15-(CH2)P-
CONHSO RB, wherein p is 0 to 6 and R 5 is H or loweralkyl. In a further embodiment, RA is hydrogen and R4 is
CH NH- CHRi5-(CH2) -COOH, wherein p is 0 to 6 and R15 is H or loweralkyl. In yet a further embodiment, RA is methyl and K is wherein m is 1 to 6 and R is H or loweralkyl. In one 4 CH 2NH-CHRI 5-(CH 2)H -NHSO 2RB, 1
embodiment, RA is me yl and R4 is CH2NH- CHRI -(CH 2)P-CONHSO 2RB, wherein p is O to 6 and R1s is H or
loweralkyl. In another embodiment, RA is methyl and R4 is CH2NH- CHR1; -(CH2)P-COOH, wherein p is Oto 6 and R is H or loweralkyl,
[0021] In a further embodiment of any of the aforementioned embodiments, R is selected from the group consisting of
(1) OH, (2) 1-adamantanamino, (3) 2-adamantanamino, (4) 3-amino- 1-adamantanamino, (5) l-amino-3-adamantanamino, (6) 3-loweraIkylamino-1-adamantanamino,
(7) l-loweralkylamino-3-adamantanamino, (8) amino
(9) NR13R 14 wherein R 1 and Ri4 are each independently selected from the group consisting of hydrogen, loweralkyl, substituted loweralkyl, cycloalkyi, substituted cycloalkyl, aminoloweralkyl wherein the amino portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryktyl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy or
R J3 and R] together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group
consisting of (a) halogen,
(b) hydroxy, (c) Ci-Cj-allcoxy,
(d) C,-C3-alkoxy-Cj-Crali:oxy, (e) oxo,
(h) halo-Cr Clr alkyl, (i) amino,
(J) alkylamino,
(Ic) dialkylamino,
and
(1) CrCj-alkoxy-Ci-C -alkyl.
[0022] In a further embodiment, R3 is OH. In another embodiment, Rj is 2-adamaatanamino. In yet another embodiment, j is dimethylamino. In one embodiment, R is dimcthylaminoethylamino. In another embodiment, R is N-methylpiperazino.
[0023] In a further embodiment of any of the aforementioned embodiments, R1 and Rj are each independently selected from the group consisting of
a) hydrogen,
b) CrCralkyl,
c CrCia-alkyl substituted with one or n of
(a) halogen, (b) hydroxy,
(c) Cr Ci2-alkoxy,
( « 9 Cr C3-alkoxy- C,-C3-aIkoxy, amino,
(i) alkynyl, G) Ci-Ci2-thioa]koxy, d) Ci-C ] -alkyl substituted with aryl, ) Cj-Ciz-alkyl substituted with substituted aryl, f) Cr Ci2-alkyl substituted with heteroaryl, g) Ci-Ci 2-alky] substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j ) heterocycloalkyl, or R and R.2 taken together with the atom to which they are attached form a substituted heteroaryl or 3-10 membered heterocycloalkyl ring which optionally contains one to two hetero functionalities selected from Ihe group consisting of O , -N-, -NH, -N(Ci-C 6- alkyl}-, -N(aryl)-, -N(aryl- CrQ-alkyl-)-, -N(substituted-aryl- C,-C 6-alkyl-)-, - N(heteroaryl)-, -N(heteroatyl- Cr C6-alkyl-)-, -N(substituted-heteroaryl- Cr Q-alkyl-)-, and -S- or S(O) - wherein n is 1 or 2 and the 3- 10 membered heterocycloalkyl ring is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-C 3-alkoxy, (d) (e) OXO (f) Cj-Cj-alkyl (g) halo-C r Cr alkyl, (h) CrCa-alkoxy-d-Cj-alkyl, and k) C(O) R7, 1) C(=0) CH R8NR9R10 wherein R , R and R1 are each mdependently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R8 and i0 or R and RJ taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-C alkoxy, (d) Ci-C 3-alkoxy-C 1-C3-alkoxy, (e) 0X0, (f) q-Cs-alkyl, (g) halo-Ci-Cj-alkyl, (h) Ci-C 3-alkoxy-Ci-C 3-alkyl, [0024] In a further embodiment of any of the aforementioned embodiments, Ri and R2 are hydrogen. In another embodiment, R 1 is Ci-C 12-alkyl and R2 is hydrogen. In yet another embodiment, Ri is Ci-Cn-alkyl substituted with aryl or substituted aryl and R2 is hydrogen. In a further embodiment, Ri is C(=O)Ci-Ci 2-alkyl and R2 is hydrogen. In yet a further embodiment, Ri is C(=O) CH2 NH Cr C i2-alkyl and R2 is hydrogen. In one embodiment, R is Ci-Ci 2- alkyl substituted Q-C^-alkoxy and R is hydrogen. In another embodiment, Ri is CrC^-alkyl substituted C1-Ci2- thioalkoxy aad R2 is hydrogen. In yet another embodiment, R 1 is Ci-C^-alkyt substituted Cj-Cjj-alkylamino and R is hydrogen. [0025] In a further embodiment of any of the aforementioned embodiments, R is selected from the group consisting of (1) hydrogen, (2) cycloalkyl, (3) cycloalkenyl, (4) Ci-C I2-alfcyl, (5) Ci-C -alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cr C12-alkoxy, (d) Ci-Cr alkoxy- Q-Cj-alkoxy, (e) -COOR 5 wherein R5 is hydrogen or loweralkyl, (f) -C(O)NR 5R wherein R5 is as previously defined and R is hydrogen or loweralkyl, (g) amino, (h] -NRsRe wherein R5 and R6 are as previously defined, or R5 and R6 are taken together with the atom to which they are attached from a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (i) halogen, (ii) hydroxy, (ϋi) CrC 3-alkoxy, (iv) Ci-A-alkoxy-Ci-Cs-alkoxy, (v) oxo, (vii) halo-Ci-Ciralkyl, and (vϊ iϊ) Ci-Cj-alkoxy-C-Ciralkyl, (i) aryl, G) substituted aryl, 0 heteroaryl, (1) substituted heteroaryl, (m) mercapto, σ (n) Cr C12-thioalk y, (6) C(=O)O Rii, wherein Ri is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, (7) C(=O)N R 11Ri2,wherein R 11is as previously defined and R is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or Rn and R!2 together with the atom to which they are attached form a 3-10 raembered heterocycloalkyl ring, which is optionally substituted with one or more substitueπts independently selected from the group consisting of (a) halogen, (b) hydroxy, (c) Q-Q-alkoxy, (d) Ci-Cj-alkoxy-Ci-Cs-alkoxy, (e) oxo, (f) Ci-dralkyl, (g) substituted loweralkyl, (h) halo-Ci-Ci2-alkyl, (i) ammo, (j) alkylamino, (k) dialkylamino, and (1) Cr C3-aIkoxy-Cr C|2-allcyl, or R and its connected oxygen atom taken together is halogen. [0026] In a further embodiment of any of the aforementioned embodiments, R is hydrogen. In another embodiment, R is Ci Co-alkyl In one embodiment, R is Q-C^-alkyl substituted with aryl or substituted aryl In a further embodiment, R is In yet a further embodiment, R1 s C(=O)NHCrCi 2-alkyi substituted with aryl or substituted aryl In one embodiment, R is C(=O)OCi-Ci 2-alkyl In another embodiment, R 1 is Cf=O)NHCr Ci2-alkyl substituted with heteroaryl or substituted heteroaryl. [0027] In a further embodiment of any of the aforementioned embodiments, RB is selected from the group consisting of a) aryl, b) C]-C 12-HUyI, c) Ci-Ci 2-alkyl substituted with one or more substituents selected from (he group consisting of (a) halogen, (b) hydroxy, (c) Q-Cu-alkoxy, (d) Ci-C 3-alkoxy- d C3-alkoxy, (e) amino, (g) Ci-C 12 -dial]cylamino, (h) alkenyl, (i) alkynyl, (j) C r Ci2-thysoalkoxy, d) Ci-Ci 2-alkyl substituted with aryl, e) Ci-Ci 2-alkyl substituted with substituted aryl, ) C | -C|2-alkyl substituted with heteroaryl, g) C 1-Ci 2- U y I substituted with substituted heteroaryl, ) cycloalkyl, i) heteroaryl, J heterocycloalkyl, k) substituted aryl, 1) substituted heteroaryl. [0028] In a further embodiment of any of the aforementioned embodiments, RB is CpC^-alkyl. In another ι embodiment, RB is C 1-Ci 2-aIkyl substituted with aryl or substituted aryl. In yet another embodiment, R B IS Ci-C ] alkyl substituted with heteroaryl or substituted heteroaryl [0029] a further ismbodiment of any of the aforementioned embodiments, Rc is each selected from the group consisting of a) hydrogen, b) C-Cu-alkyl, c) Q-C^-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) C r Ci2-alkoxy, (d) Cr C3-alkoxy- Cr C3-alkoxy, (e) amino, (f) Ci-C, 2-alkyIamino, (g) Ci-Ci2-dialkylamino, (h) alkenyl, (i) alkynyl, 0 ) C[-C 12-thioalkoxy, d) Ci-Ci 2-alkyl substituted with aryl, e) C]-Ci2-alkyi substituted with substituted aryl, f) Cj-Ci 2-alkyl substituted with heteroaryl, g) Ci-Ci2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j ) heterocycloalkyl, k) C(=O) R 7 wherein R7 is previously defined, 1) C(=O) CH RsNRgRiowherein R 8, R<>and R ]() are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or and R 10 or R9 and R 10 taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected fiom the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-Cj-alkoxy, (d) CrC -alkoxy-Ci-C 3-alkoxy, (e) 0x0, (f) d-Cj-alkyl, (g) hab-Ci-Q-alkyl, [0030) la a further embodiment of any of the aforementioned embodiments, R is hydrogen. In another embodiment, R is Q-C^-alkyl. In yet another embodiment, Rc is substituted with aryl or substituted aryl. In a further embodiment, Rc is C C i2-alkyI substituted with heteroaryl or substituted heteroaryl. In one embodiment, Rc is C(=O)C 1-C12-ah\yl, In another embodiment, R is C(=O) CH NH Ci-C 2-alkyL In yet another -OIkOXy. embodiment, Rc is Ci-C[ 2-alkyl substituted C 1 C 1 In a further embodiment, Rc is C r Ciralkyl substituted C1-Ci 2-HIiOaIkOXy. In yet a further embodiment, R is Cr Ci2-alkyl substituted ^-C^-alkylamino. [0031] In a further embodiment of any of the aforementioned embodiments, R and RE are each independently selected from the group consisting of a) hydrogen, b) CrCralkyl, c) CrC^-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) C]-C !2-alkoxy, (d) C,-C 3-alkoxy- C r C3-alkoxy, (e) amino, (g) CrCn-dialkylan ώio, (h) alkenyl, (i) alkynyl, (j) Ci-Ci2-thioalkoxy, ) C[-C i-alkyl substituted with aryl, e) Ci-Ci2-alkyl substituted with substituted aiyl, f) Cr Ci -alkyl substituted with heteroaryl, g) Ci-Cu-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j) heterocycloalkyl, or RD and RE taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which optionally contains one to two hetero functionalities selected from the group consisting of -O-, -N-, -MH, -N(Cr-C -alkyl)-, -N(aryl)-, -N{aryl- Cr C6-aIky]-)- - N(substituted-aryl- Ci-C6-alkyl-)-, -N(heteroaryl)-, -N(heteroaryl- Cr C6-alkyl->, -Nfsubstituted- heteroaryl- Ci-C6-alkyl-)-, and -S- or S(O) - wherein n is 1 or 2 and the 3-10 membered heterocycbalkyl ring is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) C1-C3-SIkOXy, (e) oxo, (f) Q-Cj-alkyl, (g) halo-CpCj-alkyl, (h) C1-C3-alkoxy-C1-C3-alkyl, and k) C(=O) R7 wherein R7 is previously defined, 1) C(=O) CH R NR R1Owherein R8, R and R]0 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R8 and R 10 or R and R 10 taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Cj-Cs-alkoxy, χ (d) C|-C -alkoxy-Cr C3-alko y, (e) oxo, (f) C r C3-alkyl, (g) halo-CrCj-aikyl, (h) Cr C3-aIkoxy-C 1-C3-a3kyl5 m) C(=0) CH R NR R7 wherein R7, R8 and R9 are as previously defined. [0032] Ia a further embodiment of any of the aforementioned embodiments, RD and RE are hydrogen. In another embodiment, RD is and R E is hydrogen. In yet another embodiment, RD is Cr C12-alkyl substituted with aryl or substituted aryl and RE is hydrogen. In one embodiment, R is C(=O)C r Ci2-alkyl and RE is hydrogen. In a further embodiment, RD is C(=O) CH2 NH CpCralkyl and RE is hydrogen In yet a further embodiment, R D IS Q - C^-alkyl substituted Cr Ci2-alkoxy and RE is hydrogen In another embodiment, R is Ci-C ! -alkyl substituted C]- Ci2-thioalkoxy and RE is hydrogen. In one embodiment, RD is substituted Ci-C !2-alkylamino and RE is hydrogen. [0033] In a further embodiment of any of the above structures, Y is oxygen and R4 is hydrogen. In another embodiment, Z is oxygen and R4 is hydrogen. In yet another embodiment, Y is NH and R4 is hydrogen. In a further embodiment, Z is sulfur and R4 is hydrogen. In yet a further embodiment, Z is oxygen and R4 is CH2NHCH PO3H2. In one embodiment, Y is oxygen and R4 is CH2NHCH 2PO3H2. In another embodiment, Y is NH and R4 is CH2NHCH 2PO3H2. [0034] In a further embodiment of any of the aforementioned embodiments, Ri is hydrogen and R2 is COCHRjNHRis wherein R] 5 is substituted arylalkyl and R8 is as previously defined. [0035] In another aspect are compounds selected from Compound (23) , Compound (24). Compound (25) . Compound £26), Compound {27 Compound {28}, Compound {29}, Compound £30), Compound £3J), Compound 32 . Compound 22 , Compound {34}, Compound (44). Compound £451, Compound £46 , Compound (48). Compound {49}, Compound {50}, Compound {51), Compound £571, Compound {58}, Compound £59}, Compound £60}, Compound {73}, Compound £74}, Compound £75}, Compound {76}, Compound £77}, Compound £78}, Compound £79}, Compound £80}, Compound £81}, Compound £84), Compound £85}, Compound £86}, Compound £871, Compound £88), Compound £89), Compound £90), Compound £91), Compound £92}, Compound £93), Compound £94), Compound £95), Compound £96), Compound £97}, Compound £98), Compound £29), Compound (100) . Compound (101). Compound (102). Compound (103) . Compound (104) , Compound (105) . Compound (106). Compound (107) . Compound (108) . Compound (124). Compound (125) . Compound (126) . Compound (127) . Compound (128) . Compound (129). Compound (130) . Compound (131) . Compound (132) . Compound (133) . Compound (J34) . Compound (135). Compound (136). Compound £137), Compound (138) . Compound (140). Compound (141) . Compound (142) . Compound (143) . Compound (145) . Compound (151) . Compound (152) . Compound (153) . Compound (154). Compound (155) . Compound (156) . Compound (157) . Compound (158) . Compound (159). Compound (160). Compound (161) . Compound (163) . Compound (164) . Compound (165) . Compound (166). Compound (167). Compound (168) . Compound (169) . Compound (170) . Compound (171) . Compound (172) . and Compound (173) . [0036] In another aspect are pharmaceutical compositions comprising a therapeutically effective amount of any of the aforementioned compounds, together with a pharmaceutically acceptable earner. [0037] Ia another aspect are methods of treating a mammal in need of such treatment comprising administering to the mammal an antibacterial effective amount of any of the aforementioned compounds together with a pharmaceutically acceptable earner In one embodiment, the mammal has a bacterial infection that is resistant to another antibiotic, including vancomycin, desmethylvancomycin, eremomycin, tetcoplanin (complex of five compounds), dalbavancin, ontavancin, telavancin, and A82846B (LY264826) having compounds having structures A B, C, D, E, F, G and H; or combinations of such antibiotics. [0038] In another aspect, described herein is the use of a compound described herein in the manufacture of a medicament for the treatment of a bacteπal-related disease or condition Ia one embodiment, the bactenal-related disease or condition arises from a bacteria that is resistant to another antibiotic, including vancomycin, desmethylvaneorαycin, eremomycin, teicoplanm (complex of five compounds), dalbavancin, ontavancin, telavancin, and A82846B (LY264826) having compounds having structures A, B, C, D, E, F, G and H, or combinations of such antibiotics [0039] In another aspect, descπbed herein are articles of manufacture, comprising packaging material, a compound of any of Formula I, Formula II, Formula HI, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, Formula XI or Formula XII, which is effective for treatment, prevention or amelioration of one or more symptoms of a bacterial-mediated disease or condition, within the packaging material, and a label that indicates that the compound or composition, or pharmaceutically acceptable salt, pharmaceutically acceptable N- oxide, pharmaceutically acceptable acyl glucuroide metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, is used for treatment, prevention or amelioration of one or more symptoms of a bacterial-mediated disease or condition, are provided [0040] In another aspect are methods of making a compound of Formulas I-V and XI, comprising, modifying a compound from the group consisting of Formulas 1, U, Hi, iv and v, wherein R is hydrogen or methyl, X is chlorine or hydrogen, R3 is alkoxy, 2-adamantanamino, or loweralkylamino as defined herein, or R4 is hydrogen or properly protected CH2NHCH2PO3H2, or Boc-aminoloweralkyl as defined herein, by a technique selected from the group consisting of, (a) acylation of the primary amide group of the 3 amino acid asparagine with an RB-isocyanate or RB-thioisocyanate in the presence of a base such as dimemylaminopyridine and the like, (b) removal of the Boc protecting group with mild acid such as trifluoroacetic acid, (c) if the R is alkoxy, removal of the alkoxy group by mild base or acid hydrolysis to give the carboxylic acid derivative, (d) reduction of the azide function to an amine, (e) alkylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4 amino acid of the compound with an alkyl halide having structure R1-J where J is a halogen or Rc-J where J is a halogen (1) acylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4* amino acid of the compound with an acyl group having the structure, C(=0) R7, (g) acylation of the primary alcohol of the mono-sugar or the amino substituent on the ammo- substituted sugar moiety of the 4th amino acid of the compound with an acyl group having the structure, C( O) CHR8NR9RiO, (h) reaction of the amino substituent on the amino-substituted sugar moiety of the 4 amino acid of the compound with an aldehyde or ketone followed by reductive amination of the resulting imine, (i) conversion of the acid moiety on the macrocyclic ring of the compound with substituted amide as defined by R3, Q) phosgene reaction on primary alcohol or primary amine of the mono- sugar moiety of the 4th amino acid of the compound with the adjacent hydroxyl group, (k) dipolar cycloaddition of the azide with alkyne to form 1,2,3-trizole, (1) a combination of (a) and (b), (m) a combination of (a), (b) and (c), (n) a combination of (a), (c), (i) and (b), (o) a combination of (a), (e), and (b), (p) a corabmation of (a), (f) and (b), (q) a combination of (a), (g) and (b), (r) a combination of (a), (h) and (b), (s) a combination of (a), (d) and (b), (t) a combination of (a), (d), (c) and (b), (u) combination of (a), (c), (i), (d) and (b), (v) a combination of (a), (c), (d) and (b), (w) a combination of (a), (c), (i), (d), (e) and (b), (x) a combination of (a), (c), (i), (d), (f) and (b), (y) a combination of (a), (c), (i), (d), (g) and (b), (z) a combination of (a), (c), (i), (d), (h) and (b), (aa) a combination of (a), (c), (d), (e) and (b), (bb) a combination of (a), (c), (d), (f) and (b), (cc) a combination of (a), (c), (d), (g) and (b), (dd)a combination of (a), (c), (d), (h) and (b), (ee) a combination of (a), (j), and (b), (ff) a combination of (a), (j), (c), (i) and (b), (gg) a combination of (a), (d), (j), and (b), (hh) a combination of (a), (d), (j), (c), (ϊ) and (b), (ϋ) a combination of (a), (k), and (b), Oj) a combination of (a), (k), (c), (i) and (b), rm a compound having a formula selected from the group consisting of, and wherein R, R , R2,R3,R4, RA, RB, RC. X , Y, and Z are as defined herein. another aspect are methods of making a compound of Formulas VI-X and XII, comprising: modifying a compound from the group consisting of Formulas vi, vϋ, vϋi, i and x, wherein RA is hydrogen or methyl, X is chlorine or hydrogen, R 3is alkoxy, 2-adamantanamino, or loweraJkylamino as defined herein, or R is hydrogen or properly protected CH2NHCH2PO3H , or Boc-aminoloweralkyl as defined herein, by a technique selected from the group consisting of, (a) Hofmann degradation of the primary amide group of the 3rd amino acid asparagine with phenyliodine-bis-trifluoroacetate to give the primary amine, (b) alkylation of the primary amine with an alkyl halide having structure Rp-J where J is a halogen or RE-J where J is a halogen, (c) acylatiott of the primary amine with an acyl group having the structure, C(=O) R7, (d) acylatiott of the primary amine with an acyl group having the structure, C(=O) CHR8NR9Ri0, (e) removal of the N-Alloc protecting group with the use of Pd(OAc) , PPh , and (nBu) SnH, (i) hydrolysis of all acetate groups to give the alcohol, (g) if the R3 is alkoxy, removal of the alkoxy group by mild base or acid hydrolysis to give the carboxytic acid derivative, (h) alkylation of the primary alcohol of the mono-sugar or the amino substitaent on the amino- substituted sugar moiety of the 4 amino acid of the compound with an alkyl halide having structure R-J where J is a halogen, R]-J where J is a halogen or R -J where J is a halogen (i) acylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4 amino acid of the compound with an acyl group having the structure, C(=0) R7, (j) acylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4th amino acid of the compound with an acyl group having the structure, C(=0) CHR8NR9R10, (k) reaction of the amino substituent on the amino-substituted sugar moiety of the 4t amino acid of the compound with an aldehyde or ketone followed by reductive amination of the resulting imine, (IJ conversion of the acid moiety on the macrocyclic ring of the compound with substituted amide as defined by R3, (m) phosgene reaction on primary alcohol or primary amine of the mono- sugar moiety of the 4* amino acid of the compound with the adjacent hydroxy! group, (n) a combination of (a), (e) and (f), (o) a combination of (a), (b), (e) and (f), (p) a combination of (a), (c), (e) and (f), (q) a combination of (a), (d), (e) and (f), (r) a combination of (a), (c), (e), (f) and (g), (s) a combination of (a), (c), (e), (f), (g) and (1), (t) a combination of (a), (d), (e), (fj and (g), (u) a combination of (a), (d), (e), (f), (g) and (1), (v) a combination of (a), (c), (e), (h) and (f), (w) a combination of (a), (d), (e), (h), and (f), (x) a combination of (a), (c), (e), (h), (f) and (g), (y) a combination of (a), (d), (e), (h), (f) and (z) a combination of (a), (c), (e), (h), (f), (g) and (1), (aa) a combination of (a), (d), (e), (h), (f), (g) and (1), (bb) a combination of (a), (c), (e), (i) and (f), (cc) a combination of (a), (d), (e), (i), and (f), (dd) a combination of (a), (c), (e), (i), (f) and (g), (ee) a combination of (a), (d), (e), (i), (f) and (g), (ff) a combination of (a), (c), (e), (i), (f), (g) and (I)1 (gg) a combination of (a), (d), (e), (i), (f), (g) and (1), (hh) a combination of (a), (c), (e), (j) and (f), (ii) a combination of (a), (d), (e), (J), and (f), (U) a combination of (a), (c), (e), (j), (f) and (g), (kk) a combination of (a), (11) a combination of (a), (c), (e), (j), (Q, (g) and (1), (mm) a combination of (a), (d), (e), (j), (f), (g) and (I)1 (nn) a combination of (a), (c), (e), (k) and (f), (oo) a combination of (a), (d), (e), (k), and (f), (pp) a combination of (a), (c), (e), (k), (f) and (g), (qq)a combination of (a), (d), (e), (k), (f) and (g), (rr) a combination of (a), (c), (e), (k), (f), (g) and (1), (ss) a combination of (a), (d), (e), (k), (f), (g) and (1), a compound having a formula selected from the group consisting of: wherein R,Rf, R ,R3,R4, RA, R C D. RE> , Y d are as defined herein. DETAILED DESCRIPTION [0042] The materials and associated techniques and apparatuses described herein will now be described with reference to several embodiments. Important properties and characteristics of the described embodiments are illustrated in the structures in the text. While the compositions, compounds and methods described herein are described in conjunction with these embodiments, it should be understood that the compositions, compounds and methods described herein are not to be limited to these embodiments. On the contrary, the compositions, compounds and methods described herein cover alternatives, modifications, and equivalents as are included within the spirit and scope of the appended claims. In the following description, numerous specific details are set forth n order to provide a thorough understanding of the compositions, compounds and methods described herein. The compositions, compounds and methods described herein are optionally practiced without some or all of these specific details Well known process operations have not been described in detail in order not to unnecessarily obscure the compositions, compounds and methods described herein. [0043] There is a continuing need to identify new derivative compounds which possess improved antibacterial activity, which have less potential for developing resistance, which possess improved effectiveness bacterial infections that resist treatment with currently available antibiotics, or which possess unexpected selectivity against target microorganisms. [0044] Therefore, described herein are semi-synthetic glycopeptides that have antibacterial activity. The semi¬ synthetic glycopeptides descπbed herein are based on hydrolysis of the disacchande moiety of the amnio acid-4 of the parent glycopeptide to monosaccharide, conversion of the monosaccharide to the ammo-sugar, acylation of the amino substituent on the ammo-substituted sugar moiety on these scaffolds with certain acyl groups, and conversion of the acid moiety on the macrocychc ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate or carrying a Hofraann degradation of the primary amide of the rd amino acid asparagine ε with phenyl-bis-trifluoroacetate to give the primary amine Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of fee compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections Compounds [00451 Descnbed herein are compounds having a structure selected from the group consisting of Formulas I , IT HI, IV, V, VI, Vn, Vm, IX, X , XI, and XII. wherein, R is selected from the group consisting of a) hydrogen, b) methyl, c) Cr Cir alkyϊ; R 1 and R2 are each independently selected from the group consisting of a) hydrogen, b) CrC 12-al]cyl, ) Q-C^-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-Ci 2-alkoxy, (d) C C3-alkoxy- C r C3-alkoxy, (e) ammo, (f) Cr Ci2-alkylamino, (a) alkenyl, (i) alkynyl, ()) C]-C,2-thioalkoxy, ) C -Cu-alkyl substituted with aryl, e) Ci-Ci 2-alkyl substituted with substituted aryl, f) Ci-C]2-alkyl substituted with heteroaryl, g) substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j) heterocycloalkyl, or Ri and R2 taken together with the atom to which they are attached form a substituted heteroaryl or 3-10 membered heterocycloalkyl nng which optionally contains one to two hetero functionalities selected from the group consisting of-O-, -N-, -NH, -N(Ci-Ce- alkyl)-, -N(aryl)-, -N(aryl- d-C -alkyl-)-, -N(substituted-aryl- CpCe-alkyl-)-, - N(heteroaryl)-, -N(heteroaryl- C,-C 6-alkyl-)-, -N(substituted-heteroaryl- Cr Ce-alkyl-)-, and -S- or S(O)n wherein n is 1 or 2 and the 3- 10 membered heterocycloalkyl ring is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-Cj-aikoxy, (d) Ci-Cralkoxy-CrCj-alkoxy, (e) oxo, (D Cr C3-alkyl (g) halo-Ci-C 3-alkyl, (h) C 1-C3-alkoxy-C r C -al]cyl, and k) C(-O) RT, 1) C(=O) CH Rj NRpRiowherein R8, R and R are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R8 and R i0 or R and Ri0 taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-C 3-alkoxy, (d) Cr C3-aIkoxy-C,-Cralkoxy, (e) oxo, (f) C 1-C 3- yI, (g) halo-C r C3-alkyl, (h) Cj-C r alkoxy-C r C3-alkyl; R is selected from the group consisting of a) hydrogen, b) Cr C ir alkyl, c) CpC -alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (d) Ci-C 3-alkoxy-Ci-C 3-alkoxy, (e) amino, (f) C]-Ci2-alkylamino, (g) Ci-C 2-dialkylamuio, (h) alkenyl, (i) allcynyl, (j) Ci-Cu-thioalkoxy, ) Ci-C 12-aUcyi substituted with aryl, e) C,-C] 2-alkyl substituted with substituted aryl, f) Cr C 12-aIkyI substituted with heteroaryl, B) Ci-C -alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j ) heterocycloalkyl, ) Ci-Ci 2-alkylamino; X s selected from the group consisting of (1) hydrogen, (2) chlorine, Y is selected from the group consisting of (1) oxygen, (2) NRi, wherein Ri is as previously defined, Z is selected from the group consisting of (1) oxygen, (2) sulfur, R is selected from the group consisting of (D hydrogen, (2) cycloalkyl, (3) cycloalkenyl, (4) C,-C 12-alkyL (5) C r Ci2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) CpCu-alkoxy (d) C r C3-alkoxy- C,-C 3-aIkoxy, (e) -COOR 5 wherein R 5 is hydrogen or loweralkyl, (f) -C(O)NR R6 wherein R5 is as previously defined and R6 is hydrogen or loweralkyl, (g) amino, (h) -NR 5R wherein R5 and R6 are as previously defined, or R5 and R are taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (i) halogen, (u) hydroxy, (m) C1-C3-BIkOXy, (iv) Ci-C -alkoxy-C r Cr alkoxy, (v) oxo, (Vi) CrC I2-alkyl, (vii) halo-Ci-Cu-alkyl, and (viii) Cr C -alkoxy-C r Cj2-alkyl, (J) substituted aryl, (k) heteroaryl, (1) substituted heteroaryl, (m) mercapto, (n) Ci-Ci 2-thioalkoxy, (6) C(=0)0 Rn, wherein R 11is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, (7) C(=0)N Rn R i2, wherein R u is as previously defined and R 12 is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R and R12 together with the atom to which they are attached form 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, O ) hydroxy, (c) Ci-C 3-alkoxy, (d) CrC 3-alkoxy-Ci-C r alkoxy, (e) 0x0, (f) C,-C 12 -alkyl, (g) substituted loweralkyl, (h) halo-C r Cj2-alkyl, (i) amino, (j) alkylamino, (k) dialkylamino, and (1) Ci-C 3-HIkOXy-C1-C12-HhCyI, or R and its connected oxygen atom taken together is halogen; R is selected from the group consisting of (1) OH, (2) 1-adamantanaraino, (3) 2-adamantanamino, (4) 3-ammo-l-adamantanamino, (5) l-a πiino-3-adamantanatnino, (6) 3-loweralkylamino-l-adamantaaamino, (7) l-loweralfcylamino-3-adamantanamino, (8) amino, (9) NRi3R wherein R13 and R14 are each independently selected from the group consisting of hydrogen, loweralkyl, substituted loweralkyl, cycloalkyl, substituted cycloalkyl, aminoloweralkyl wherein the amino portion of the aminoloweralkyl group s further substituted with unsubstituted or substituted alkyl, alkenyl, cycioalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy or R and R14 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cr C3-alkoxy, (d) Ci-Cs-alkoxy-Ci-Cs-alkoxy, (e) oxo, (f) C,.C 12 -alkyl, (g) substituted loweralkyl, (h) hab-Ci-C 12-aIkyl, (0 amino, 0) alkylamino, (k) dialkylamino, and (I) C,-C3-alkoxy-Cr C,2-alkyl, R is selected from the group consisting of CH INM-CHR -(CH ) NH SO RB, (1) 13 2 2 wherein m is 1 to 6 and Ri5 is H or loweralkyl, (2) CH2NH- CHR15 -(CH2)p-CONHSO2RBl wherein p is 0 to 6 and R 15 s H or loweralkyl, (3) CH2NH- CHRj5 -(CH2VCOOH 1wherein p is 0 to 6 and R15 is H or loweralkyl, (4) CH NRF-CHR -(CHJ) -NR SO R , wherein q is 2 to 4 and R is H or loweralkyl, R 15 1 3 2 B 15 and R are independently hydrogen, lower alkyl or taken together represents a -CH2- , (5) H, (6) CH NHCH PO H2, (7) aminoloweralkyl wherein the ammo portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy, R IS selected from the group consisting of a) aryl, b) q-Cralkyl, c) C|-C12-alkyl substituted with one or more substituents selected from (he group consisting of (a) halogen, (b) hydroxy, κ (c) Ci-C 12-alko y, (d) Ci-C3-alkoxy- Cr C3-alkoxy, (e) amino, (f) Cr Ci2-alkylainino, (h) alkenyl, (i) alkynyl, (j) Ci C -thioalkoxy, d) CrC -alkyl substituted with aryl, e) Ci-Ci 2-alkyl substituted with substituted aryl, f) C[-Ci2-alkyl substituted with heteroaryl, g) Cr Ci2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) heteroaryl, j ) heterocycloalkyl, k) aryl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) d-Cij-alkoxy, κ (d) C r C6-alkoxy- Cr C6-alko y, (e) amino, (f) amino-Ci-C«-alkoxy, (g) Ci-C^-alkylaniino, (h) C]-C6-alkoxy (i) Cr C12-dialkylamino, (j) Ci-Cirdialkylamino- Ci-Cg-alkoxy, (k) alkenyl, (1) alkynyl, (EI) Ci-Ct2-thioalkoxy, (n) Q-dmlkyl, 1) heteroaryl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-C l2-alkoxy, (d) C1-CVaIkOXy- Cr Cr alkoxy, (c) amino, (f) araino-Ci-C 6-alkoxy, (g) C|-C[ 2-alkylamino, (h) Ci-C l2-alkykmino- Cr C -alkoxy, π (i) Ci-Ci2-dialkyla iino, (j) Ci-Cu-dialkylamiiiD- Cr C6-alkoxy, (k) alkenyl, (i) alkynyl, (m) Ci-C^-thioalkoxy, (n) C -alkyl; Rc is each selected from the group consisting of a) hydrogen, b) CrCu-alkyl, c) Ci-C l2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-Cu-alkoxy, (d) C^-alkoxy- Cr C3-alkoxy, (e) amino, (f) C|-C 12-aHylamino, (g) Ci-C 12-dialkylamino, (h) alkenyl, (i) aliynyl, (j) Cr C]2-thioalkoxy, d) C,-C !2-alkyl substituted with aryl, e) Ci-Ci 2-alkyl substituted with substituted aiyi, f) Ci-C 12-alkyl substituted with heteroaryl, g) Ci-Ci 2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloaUcenyl, j) heterocycloalkyl, k) C(=O) R7 wherein R7 is previously defined, 1) C(=O) CHR NR9RiOwherein R , R9 and R 10 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R8 and Ri0 or R and R1 taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (C) C|-C 3-alkoxy, (d) C r C3-alkoxyA-C 3-aUcoxy, (e) oxo, (f) Cr C3-alkyl, (g) halo-C r C3-alkyl, RD and RE are each independently selected from the group consisting of a) hydrogen, b) C r C]2-alkyl, c) Ci-Ci 2-alky] substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) C -C n - o y, (d) Cj-C3-a!koxy- C r C alkoxy, (e) amino, (f) Ci-Cia-alkylamino, (g) Ci-Cirdialkylamino, (h) alkenyl, (i) alkynyl, (j) CrC -thioalkoxy, ) Ci-Cn-all-yl substituted with aryl, e) Cr C12-aIkyl substituted with substituted aryl, C1-C i2-alkyl substituted with heteroaryl, g) C[-Ci2-alkyl substituted with substituted heteroaryl, h) cycioalkyl, i) cycloalkenyl, j) heterocycloalkyl, or R and RE taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which optionally contains one to two hetero functionalities selected from the group consisting of-0-, -N-, -NH, -N(C r C -alkyl)-, -N(aryl)-, -N(aryl- Ci-C 6- alkyl-)-, -N(substituted-aryl- Cr C -aIkyl-)-, -N(heteroaryl)-, -N(heteroaryl- C r Q-alkyl-)-, -N(substituted-heteroaryl- and -S- or S(O) - wherein n is 1 or 2 and the 3- 11 10 membered heterocycloalkyl ring is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-C3-alkoxy, (d) Cr C3-alkoxy-Ci-C -allcoxy, (e) oxo, (f> Cr C3-alkyl; (g) hab-C C3-aIkyl, (h) Ci-C3-alkoxy-Ci-C3-alkyl, and k) C(O) R7 wherein R is previously defined, 1) C(=0) CH R8NR9R1 wherein R8, R and R]0 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryt, substituted aryl, heteroaryl or substituted heteroaryl, or R8 and Ri or R and Ri0 taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) C-Cj-alkoxy, (d) Ci-C -alkoxy-Ci-Cralkoxy, (e) oxo, (f) Cr C3-alkyl, (g) halo-Ci-C -alkyl, (h) Ci-Cralkoxy-CrCj-alkyl, m) C(=0) CH R8NR9R wherein R7, R8 and R are as previously defined, or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof [0046] Also provided herein are pharmaceutical compositions which comprise a therapeutically effective amount of a compound as defined above in combination with a pharmaceutically acceptable carrier or diluent. [0047] According to the methods of treatment provided herein, bacterial infections are treated or prevented in a patient such as a human or lower mammal by administering to the patient a therapeutically effective amount of a compound provided herein, m such amounts and for such time as is necessary to achieve the desired result [0048] In a further aspect are provided processes and intermediates for the preparation of semi-synthetic glycopeptides of Formulas I, H ID, IV, V, VI, VII, VHI, IX, X, XI, and X above. [0049J In another embodiment are provided compounds of Formulas II, I VII, and VIII wherein R1 is hydrogen and R2 are selected from the group consisting of hydrogen, unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, arylalkyl, alkylaryl, and heteroaryl, and said aryl, alkylaryl, arylalkyl or heteroaryl group optionally containing one or more optionally substituted aryl, heteroaryl, or condensed rings, C(=O) R7 C(=O) or Ri and R together with the atom to which they are attached form a substituted heteroaryl or cycloheterocyclic πng which optionally contains additional heteroatom selected from the group consisting of optionally substituted O, N, and S In specific embodiments, R2 is hydrogen or methyl substituted with an unsubstituted or substituted biphenyl, for example biphenyl or chloro-biphenyl. [0050] In another embodiment are provided compounds of Formulas I - X and XII wherein R 7 is selected from the group consisting of a) hydrogen, b) C]-C1r a yl, ) Ci-Ci2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-C -altoxy, (e) amino, (f) Ci-Ci2-alkylamino, (g) Ci-Cn-dialkylamino, (h) alkenyl, (i) alkynyl, C) Ci-Cu-tnioalkoxy, d) Cr C12-alkyl substituted with aryl, e) Ci-Ci -alkyl substituted with substituted aryl, f) Ci-Cn-alkyl substituted with heteroaryl, g) C]-Ci2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j) heterocycloalkyl, k) Cr C]2-alkylamino. [0051] In another embodiment are provided compounds of Formulas I and VI wherein R is selected from the group consisting of (1) hydrogen, (2) cycloalkyl, (3) cycloalkenyl, (4) Cr Cir alkyl, (5) substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) CpCn-alkoxy, (d) Ci-Cj-alkoxy- Cr C3-alkoxy, (e) -COOR5 wherein R5 is hydrogen or loweralkyl, (f) -C(O)NR5R6 wherein R5is as previously defined and R6 is hydrogen or loweralkyl, (g) amino, (h) -NR 5R wherein R5 and R are as previously defined, or R5 and R are taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (i) halogen, (ii) hydroxy, (iii) Ci-C -alkoxy, ι (iv) C -Cr aϊkoxy-C r Cr aik.oxy, (v) oxo, (vi) C-Cralkyl, (vii) halo-Ci-Ci2-alkyl, and (viii) Ci-C3-alkoxy-Ci-Ci2-alkyl, (l) aryl, (j) substituted aryl, (k) heteroaryl, (1) substituted heteroaryl, (m) mercapto, (α) CrC -thioalkoxy, (6) C(O)O R1[,wherein R1 is hydrogen, loweralkyL substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, (7) C(=0)N Rn R 1 ,wherein Rn is as previously defined and Ri2 is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or Rn and R1 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cr C -alkoxy, (d) C,-C alkoxy-C|-Cr alkoxy, (e) oxo, (f) Cj-C12-alkyl, (g) substituted loweralkyl, (h) halo-CrCralkyl, (i) amino, (j) alkylamino, (k) dialkylamino, and (I) C-Cj-alkoxy-Ci-Cn-alkyl, or R and its connected oxygen atom taken together is halogen. [0052] In another embodiment are provided compounds of Formulas I - XII wherein X is chlorine and R4 is hydrogen. [0053] In another embodiment are provided compounds of Formulas I - XII wherein X is hydrogen and R is hydrogen. [0054] In another embodiment are provided compounds of Formulas XI and XII wherein Y is oxygen and R4 is hydrogen. [0055] In another embodiment are provided compounds of Formulas XI and XII wherein Y is NH and R4 is hydrogen. [0056] In another embodiment are provided compounds of Formulas I-V and XI wherein Z is oxygen and R4 is hydrogen. [0057] In another embodiment are provided compounds of Formulas I-V and XI wherein Z is sulfur and R is hydrogen. [0058] In another embodiment are provided compounds of Formulas I-IV, VI-IX and XI-XII wherein RA is methyl and R is hydrogen, [0059] In another embodiment are provided compounds of Formulas I-IV, VI-IX and XI-XII wherem RA is hydrogen and R4 s hydrogen. [0060] In another embodiment are provided compounds of Formulas I-IV, VI-IX and XI-XII wherein RA is methyl or hydrogen and R 3 is selected from the group consisting of (D OH, (2) l-adamantanamino, (3) 2-adamantanamino, (4) 3-amino-l-adamantanamino, (5) l-amino-3-adamantaπamuio, (6) 3-loweralkylamino-l-adamantanamino, (7) l-loweralkylamino-3-adamantanamino, (8) amino (9) NRi3R 1 wherein R 13 and R 1 are each independently selected from the group consisting of hydrogen, loweralkyl, substituted loweralkyl, cycloalkyl, substituted cycloalkyl, aminoloweralkyl wherein the ammo portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy or Ri3 and R 14 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cr C3-aikoxy, (d) Ci-Cj-alkoxy-Cr C alkoxy, (e) oxo, (f) Q-C^-alkyl, (g) substituted loweralkyl, (h) halo-Cr Ci2-a]kyl, (i) amino, (j) alkylamino, (k) dialkylamino, and (1) Cr C3-alkoxy-Ci-Ci2-alkyl. [0061] In another embodiment are provided compounds of Formulas I-IV, VI-IX and XI-XII wherein RA is methyl or hydrogen and R is selected from the group consisting of (1) (CH NH-CHR 1J-(CH2) rNHSO 1RB, wherein ra is 1to 6 and R,5 is H or loweralkyl, (2) CH2NH- CHRu -(CH2)P-CONHS0 2RB, wherein p is 0 to 6 and R 5 is H or loweralkyl, (3) CH2NH- CHR15 -(CH2) -COOH, wherein p is 0 to 6 and R15 is H or loweralkyl, (4) CH 2NRF-CHRI S-(CH2 -NRGSO2RB wherein q is 2 to 4 and Ri5 is H or loweralkyl, RF and RGare independently hydrogen, lower alkyl or taken together represents a - CH1- , (5) H, (6) CH2NHCH PO3H2, (7) aminoloweralkyl wherein the amino portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycfoalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy. [0062] In another embodiment are provided intermediate compounds of Formulas i, Ii Ui, iv, v, vi, vii, viϋ , ix, and x wherein RA is hydrogen or methyl, X is chlorine or hydrogen, and R4 is hydrogen, CH2NHCH POSH2 or aminoloweralkyl, R3 is alkoxy or amino for the synthesis of antibacterial agents of Formulas I-XII. Definitions [0063] Unless otherwise noted, terminology used herein should be given its normal meaning as understood by one of skill in the art. [0064] The term "aJkyl" as used herein refers to saturated, straight- or branched-chain hydrocarbon radicals derived from a hydrocarbon moiety containing between one and twenty carbon atoms by removal of a single hydrogen atom. [0065] The term substituted alkyl as used herein refers to alkyl substituted by one, two or three groups consisting of halogen, alkoxy, amino, alkylamino, dialkylamino, hydroxy, aryl, heteroaryl, alkenyl or alkynyl group, [0066] The term "alkenyl" as used herein refers to unsaturated, straight- or branched-chain hydrocarbon radicals derived from a hydrocarbon moiety containing between two and twenty carbon atoms by removal of a single hydrogen atom. [0067] The term "cycloalkyl" as used herein refers to a monovalent group derived from a monocyclic or bicyclic saturated carbocyclic ring compound containing between three and twenty carbon atoms by removal of a single hydrogen atom. [0068] The term substituted cycloalkyl as used herein refers to cycloalkyl substituted by one, two or three groups consisting of halogen, alkoxy, amino, alkylamino, dialkylamino, hydroxy, aryl, heteroaryl, allcenyl or alkynyl groups [0069] The term "cycloalkenyl" as used herein refers to a monovalent group derived from a monocyclic or bicyclic unsaturated carbocyclic ring compound containing between three and twenty carbon atoms by removal of a single hydrogen atom, [0070] The terms "Cr C3-alkyl", "CrQ-alkvl", and "d-C -alkyl" as used herein refer to saturated, straight- or branched-chain hydrocarbon radicals derived from a hydrocarbon moiety containing between one and three, one and six, and one and twelve carbon atoms, respectively, by removal of a single hydrogen atom. Examples of Ci-C -alkyl radicals include methyl, ethyl, propyl and isopropyl. Examples of CpCValkyl radicals include, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl and n-hexyl. Examples of Ci-C -alkyl radicals include, but not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl , n-hexyl. N-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl and n-docecyl. [0071] The term loweralkyl as used herein refers to CpC -alkyl as defined above. [0072] The term substituted loweralkyl as used herein refers to substituted by one, two or three groups consisting of halogen, alkoxy, amino, alkylamino, dialkylamino, hydroxy, aryl, heteroaryl, alkenyl or alkynyl groups. [0073] The term denoted a monovalent group derived from a monocyclic or bicyclic saturated carbocyclic ring compound by removal of a single hydrogen atom. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.I]heptyl, and bicycb[2.2.2]octyl. [0074] The terms "Cr C3-alkoxy", "Cr C6-alkoxy" as used herein refers to the Cr C3-alkyl group and Ci-C6-alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom. Examples of Cr C6- alkoxy radicals include, but not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, neopentoxy and n-hexoxy. [0075] The term "loweralkylamino" as used herein refers to CpCn-alkyl groups, as previously defined, attached to the parent molecular moiety through a nitrogen atom Examples of loweralkylamino include, but are not limited to methylamino, dimethylamino, ethylamino, diethylamino, propylamine and decylamino. [0076] The term "oxo" denotes a group wherein two hydrogen atoms on a single carbon atom in an alkyl group as defined above are replaced with a single oxygen atom (i e. a carbonyl group). [0077] The term "aryl" as used herein refers to a mono- or bicyclic carbocycϋc ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, lndanyl, indenyl and the like and is optionally un-substituted or substituted (including bicyclic aryl groups) with one, two or three substituents independently selected from loweralkyl, substituted loweralkyl, haloalkyl, Cj-Cu-alkoxy, thioalkoxy, C1-C 2- thioalkoxy, aryloxy, amino, alkylamino, dialkylamino, acylamino, cyano, hydroxy, halogen, mercapto, nitrc, carboxaldehyde, carboxy, alkoxycarbonyl and carboxamide. In addition, substituted aryl groups include tetrafluorophenyl and pentafluorophenyl. [0078] The term "substituted aryl" as used herein refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, uidanyl, indenyl and the like substituted (including bicyclic aryl groups) with one, two or three substituents independently selected from loweralkyl, substituted loweraUcyl, haloalkyl, Cr C) alkoxy, thioalkoxy, alkoxyalkylalkoxy, aryloxy, amino, aminoaUcyl, atninoalkylalkoxy, alkylamino, alkylaminoaikyl, alkylaminoalkyla!koxy, dialkylamino, dialkylaminoalkyl, dialkylaminoalkylalkoxy, acyiamino, cyano, hydroxy, halogen, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclaryl and carboxamide. In addition, substituted aryl groups include tetrafluorophenyl and pentafluorophenyl. [0079] The term "aryialkyl" as used herein refers to an aryl group as defined above attached to the parent molecular moiety through an alkyl group wherein the alkyl group is of one to twelve carbon atoms, [0080] The term "substituted aryialkyl" as used herein refers to a substituted aryl group as defined above attached to the parent molecular moiety through an alkyl group wherein the alkyl group is of one to twelve carbon atoms. [0081] The term "alkylaryl" ae used herein refers to an alkyl group as defined above attached to the parent molecular moiety through an aryl group. [0082] The term "halo" and "halogen" as used herein refer to an atom selected from fluorine, chlorine, bromine and iodine. [0083] The term "alkylamino" refers to a group having the structure -NHR' wherein R' is alkyl, as previously defined. Examples of alkylamino include methylamino, ethylamino, iso-propylamino, and the like. [0084] The term "dialkylamino" refers to a group having the structure -NHR'R" wherein R' and R" are independently selected from alkyl, as previously defined. Additionally, R' and R" taken together optionally be - (CH2V where k is an integer of from 2 to 6. Examples of dialkylamino include dimethylamino, diethylamino, methylpropylamino, piperidino, and the like. [0085] The term "haloalkyl" denotes an alkyl group, as defined above, having one, two or three halogen atoms attached thereto and is exemplified by such group as chloromethyl, bromoethyl , trifiuoromethyL and the like. [0086] The term "alkoxycarbonyl" represents as ester group; i e. an alkoxy group, attached to the parent molecular moiety through a carbonyl group such as methoxycarbonyl, ethoxycarbonyl, and the like [0087J The term "thioalkoxy" refers to an alkyl group previously defined attached to the parent molecular moiety through a sulfur atom [0088] The term "carboxaldehyde" as used herein refers to a group of formula -CHO. [0089] The term "carboxy" as used herein refers to a group of formula -CO H. [0090] The term "carboxamide" as used herein refers to a group of formula -CONHR'R" wherein R ' and R' ' are independently selected from hydrogen, alkyl, substituted loweralkyl, or R' and R" taken together optionally be - (CH3) - where k is an integer of from 2 to 6. [0091] The term "heteroaryl", as used herein, refers to a cyclic or bicyclic aromatic radical having from five to ten ring atoms in each ring of which at least one atom of the cyclic or bicyclic ring is selected from optionally substituted S, O, and N; zero, one or two ring atoms are additional heteroatoms independently selected from optionally substituted S, O, and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, lmidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl. thiophenyl, furanyl, quinolinyl, lsoquinolinyl, naphthyπdinyl, and the like. [0092] The term "substituted heteroaryl" as used herein refers to a cyclic or bicyclic aromatic radical having from five to ten ring atoms in each ring of which at least one atom of the cyclic or bicyclic ring is selected from optionally substituted S, O, and N; zero, one or two ring atoms are additional heteroatoms independently selected from optionally substituted S, O, and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, naphthyridinyl; and the like substituted with one, two or three substituents independently selected from loweralkyl, ω substituted loweralkyl, haloalkyl, Ci-C ]2-alkoxy, thioalkoxy, Cr C ir thioaU xy, alkoxyalkylalkoxy, aryloxy, amino, aminoalkyl, aminoalkylalkoxy, alkylamino, alkylaminoalkyl, alfylarmnoalkylalkoxy, dialkylamino, dialkylarninoalkyl, dialkylaminoalkylalkoxy, acylamino, cyano, hydroxy, halogen, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl, aryl, heteroaryl, heterocyclaryl and carhoxamide. [0093] The term "heterocycloalkyl" as used herein, refers to a non-aromatic partially unsaturated or fully saturated 3- to 10-membered ring system, which includes single rings of 3 to 8 atoms in size and bi- or tri-cyclic ring systems which includes aromatic six-memberβd aryl or heteroaryl rings fused to a non-aromatic ring. These heterocycloalkyl rings include those having from one to three heteroatoms independently selected from oxygen, sulfur and nitrogen, in which the nitrogen and sulfur heteroatoms optionally be oxidized and the nitrogen heteroatom optionally be quaternized. Representative heterocycloalkyl rings include, but not limited to, pyrroKdinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morphoϋnyl, thiazolidinyl, isothiazolidinyl, andtetrahydrofuryl. [0094] The term "heteroarylalkyl" as used herein, refers to a heteroaryl group as defined above attached to the parent molecular moiety through an alkytene group wherein the alkylene group is of one to four carbon atoms. [0095] "Protecting group" refers to an easily removable group which is known in the art to protect a functional group, for example, a hydroxyl, ketone or amine, against undesirable reaction during synthetic procedures and to be selectively removable. Examples of such protecting groups are known, cf., for example, T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis . 2nd edition, John Wiley & Sons, New York (1991). Examples of hydroxy-protecting groups include, but not limited to, methylthiomethyl, tert-dimethylsilyl, tert-butyldiphenylsilyl, ethers such as methoxymethyl, and esters including acetyl, benzoyl, and the like. Examples of ketone protecting groups include, but not limited to, ketals, oximes, O-substituted oximes for example O-benzyl oxime, O- phenylthiomethyl oxime, 1-isopropoxycyclohexyl oxime, and the like. Examples of amine protecting groups include, but are not limited to, tert-butoxycarbonyl (Boc) and carbobenzyloxy (Cbz). [0096] A term "protected-hydroxy" refers to a hydroxy group protected with a hydroxy protecting group, as defined above. [0097] The term amino acid refers to amino acids having D or L stereochemistry, and also refers to synthetic, non- natural amino acids having side chains other than those found in the 20 common amino acids. Non-natural amino acids are commercially available or are optionally prepared according to US 5,488,131 and references therein. Amino acids are optionally fiirther substituted to contain modifications to their amino, carboxy, or side-chain groups. These modifications include the numerous protecting group commonly used in peptide synthesis (T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis. 2nd edition, John Wiley & Sons, New York, 1991). [0098] The term "substituted heteroaryl" as used herein, refers to a heteroaryl group as defined herein substituted by independent replacement of one, two or three of the hydrogen atoms thereon with Cl, Br, F I, OH, CN, C1-Cn- allcyl, C 1-C l2-alkoxy, C r Cn -a\k.oxy substituted with aryl, haloalkyl, thioalkyl, amino, alkylamino, dialkylamino, mercapto, mtro, carboxaldehyde, carboxy, alkoxycarbonyl and carboxamide. In addition, any one substituent is optionally an aryl, heteroaryL or heterocycloalkyl group [0099] The term "substituted heterocycloalkyl" as used herein, refers to a heterocycloalkyl group as defined herein substituted by independent replacement of one, two or three of the hydrogen atoms thereon with Cl, Br, F, I, OH, CN, Ci-Ci 2-alkyl, Ci-Ci 2-alkoxy, Cr Ci2-alkoxy substituted with aryl, haloalkyl, thioalkyl, amnio, alkylamino, dialkylamino, mercapto, mtro, carboxaldehyde, carboxy, alkoxycarbonyl and carboxamide In addition, any one substituent is optionally aryl, heteroaryl, or heterocycloalkyl group. [00100] The term "stereoisomer" as used herein, refers to either of two forms of a compound having the same molecular formula and having their constituent atoms attached in the same order, but having different arrangement if their atoms ra space about an asymmetric center If asymmetric centers exist in the descnbed compounds, except where otherwise noted, the compounds described herein include the various stereoisomers and mixtures thereof. Accordingly, except where otherwise noted, it is intended that a mixture of stereo-oπentations or an individual isomer of assigned or unassigned orientation is present [00101] The term "tautomer" as used herein refers to either of the two forms of a chemical compound (hat exhibits tautomeπsm, which is the ability of certain chemical compounds to exist as a mixture of two interconvertible isomers Ui equilibrium via proton transfer. The keto and enol forms of carbonyl compounds are examples of tautomers. They are interconvertible m the presence of traces of acids and bases via a resonance stabilized anion, the enolate ion. [00102] The term "pharmaceutically acceptable salt" refers (o those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/πsk ratio For example, S M Berge, et al describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66- 1-19 (1977), incorporated herein by reference for this purpose. The salts are prepared in sttu during the final isolation and purification of the compounds described herein, or separately by reacting the free base function with a suitable organic acid Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleie acid, tartaric acid, citπc acid, succinic acid or malonic acid or by using other documented methodologies such as ion exchange Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopcntanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfoaate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotmate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylρroρionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluetiesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammoruum, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate. [00103] The term "pharmaceutically acceptable ester" refers to esters which hydrolyze in vivo and include those that break down in (he human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Representative examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates. [00104] The term "solvate" as used herein refers to a compound formed by salvation, the combination of solvent molecules wilh molecules or ions of solute composed of a compound described herein. The term "pharmaceutically acceptable solvate" refers to those solvates which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lover animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. [00105] The term "alkylated quaternary ammonium salt" as used herein refers to a compound formed by alkylation of the nitrogen atom of the primary, secondary or tertiary amine of the molecule with alkyl halide to form alkyl quaternary ammonium salt. [00106] The term "pharmaceutically acceptable prodrugs" refers to those prodrugs of the compounds described herein which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds described herein. The term "prodrug" refers to compounds that are transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B . Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for this purpose. Synthetic Methods [00107] Synthesis of the compounds described herein is broadly summarized as follows. The compounds described herein are made, for example, by chemical modifications of the Compound A, Compound B, Compound H and Compound C scaffolds. In particular, die semi-synthetic glycopeptides described herein are made by chemical modification of Compound A, Compound B, Compound H and Compound C or of the monosaccharide of glycopeptides made by subjecting the parent glycopeptide in acidic medium to hydrolyze the disaccharide moiety of the amino acid-4 of the parent glycopeptide to give the monosaccharide; protection of the amino function by t- butoxycarbonyi group, carbobenzyloxy group or allyioxycarbonyl group; conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides and treatment of the compound with isocyante. Alternatively, if amino function on the monosaccharide is required, conversion of the monosaccharide to the atnino- sugar derivative; acylation of the amino substituent on the amino-substituted sugar moiety on these scaffolds with certain acyl groups; protection of the amino function by t-butoxycarbonyl group, carbobenzyloxy group or allyioxycarbonyl group; conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides and treatment of the compound with isocyante, The compounds described herein are made, for example, by coupling the amino-sugar moiety of functionalized or unfunctionalized glycopeptides from the above scaffolds with the appropriate acyl and/or amino groups under amide formation conditions and conversion of the acid moiety on the macrocyclic ring of the resulting glycopeptide derivative to certain substituted amides, or a combination of an alkylation modification of the substituent on the ammo-substituted sugar moiety on this scaffold with certain alkyl groups or acylation modification of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups, σ-amino acid or β-amino acids or derivatives thereof, and conversion of the acid moiety on the macrocychc ring of this scaffold to certain substituted amides In another seπes, the compounds described herein are made, for example, by chemical modifications of the Compound A, Compound B, Compound H and Compound C scaffolds In particular, the semt-synthetic glycopeptides described herein are made by chemical modification of Compound A, Compound B, Compound H and Compound C or of the monosaccharide of the about glycopeptides made by subjecting the parent glycopeptide in acidic medium to hydrolyze the disaccharide moiety of the amino acid-4 of the parent glycopeptide to give the monosaccharide, protection of the amino function by t- butoxycarbonyl group, carbobenzyloxy group or allyloxycarbonyl group, conversion of the acid moiety on the macrocychc ring of these scaffolds to certain substituted amides and Hofinann degradation of the primary amide of the 3rd ammo acid asparagine with phenyl-bis-tπfluoroacetate to the primary amine In some embodiments, synthesis of compounds also involves the use of protecting or blocking groups in order to maximize yields, mnumize unwanted side products, or improve purification [00108] In particular, the semi-synthetic glycopeptides of the compounds described herein are made, for example by modifying Compound A, Compound B, Compound H and Compound C scaffolds. The glycopeptide starting material is optionally unsubstituted or substituted at the 7* ammo acid at the 4 ' position of the phenyl ring with CH2NHCH2PO H2, or aminoloweralkyl as defined herein. [00109] Selective hydrolysis of Compound A, Compound B, Compound H or Compound C in which the 7th amino acid at the 4' position of the phenyl ring substituted with hydrogen, CH NHCH PO H , or aminoloweralkyl as defined herein with acid gives the monosaccharide intermediate. [00110] In general, compound of Formulas I-V and XI, described herein are made by modifying a compound from the group consisting of Formulas i, ii, iϋ , iv and v, wherein RA is hydrogen or methyl, X is chlorine or hydrogen, R is alkoxy, 2-adamantananiino, or loweralkylamino as defined herein, or R4 is hydrogen or properly protected CH2NHCH2PO H , or Boc-aminoloweralkyl as defined herein, by a technique selected from the group consisting of, (a) acylation of the primary amide group of the 3 amino acid asparagine with an RB-isocyanate or RB-thioisocyanate in the presence of a base such as dimethylaminopyridine and the like, (b) removal of the Boc protecting group with mild acid such as trifluoroacetic acid, (c) if the R is alkoxy, removal of the alkoxy group by mild base or acid hydrolysis to give the carboxylic acid derivative, (d) reduction of the azide function to an amine, (e) alkylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4 amino acid of the compound with an alkyl halide having structure R(-J where J is a halogen or R -J where J is a halogen (f) acylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4* amino acid of the compound with an acyl group having the structure, C(=0) R7, (g) acylation of the primary alcohol of the mono-sugar or the amino substit ent on the amino- substituted sugar moiety of the 4 amino acid of the compound with an acyl group having the structure, C(=0) CHR8NR Ri0, (h) reaction of the amino substituent on the amino-substituted sugar moiety of (he 4 1amino acid of the compound with an aldehyde or ketone followed by reductive amination of the resulting imine, (i) conversion of the acid moiety on the macrocyclic ring of the compound with substituted amide as defined by R , (j) phosgene reaction on primary alcohol or primary amine of the mono- sugar moiety of the 4th amino acid of the compound with the adjacent hydroxyl group, (k) dipolar cycloaddition of the azide with alkyne to form 1,2,3-trizole, (I) a combination of (a) and (b), (m) a combination of (a), (b) and (c), (n) a combination of (a), (c), (i) and (b), (o) a combination of (a), (e), and (b), (p) a combination of (a), (f) and (b), (q) a combination of (a), (g) and (b), (r) a combination of (a), (h) and (b), (s) a combination of (a), (d) and (b), (t) a combination of (a), (d), (c) and (b), (u) a combination of (a), (c), (i), (d) and (b), (v) a combination of (a), (c), (d) and (b), (w) a combination of (a), (c), (i), (d), (e) and (b), (x) a combination of (a), (c), (i), (d), (f) and (b), (y) a combination of (a), (c), (i), (d), (g) and (b), (z) a combination of (a), (c), (i), (d), (h) and (b), (aa) a combination of (a), (c), (d), (e) and (b), (bb) a combination of (a), (c), (d), (f) and (b), (cc) a combination of (a), (c), (d), (g) and (b), (dd) a combination of {a), (c), (d), (b) and (b), (ee) a combination of (a), (j), and (b), (ff) a combination of (a), (J), (c), (i) and (b), (gg) a combination of (a), (d), (j), and (b), (hh) a combination of (a), (d), (j), (c), (i) and (b), (U) a combination of (a), (k), and (b), CJj) a combination of (a), (k), (c), (i) and (b), compound having a formula selected from the group consisting of: wherein R,R], R2 R3,R4,RA,RB,Rc, X , Y, and Z are as defined herein. [00111] In general the compounds a compound of Formulas VI-X and XD, described herein are made by modifying a compound from the group consisting of Formulas vi, vii, viii, a and x, wherein RA is hydrogen or methyl, X is chlorine or hydrogen, R3 is alkoxy, 2-adamantanamino, or loweralkylamino as defined herein, or R4 is hydrogen or properly protected CH2NHCH2PO3H , or Boc- aminoloweralkyl as defined herein, by a technique selected from the group consisting of, (a) Hofinann degradation of the primary amide group of the 3rd amino acid asparagine with phenytiodine-bis-trifluoroacetate to give the primary amine, (b) alkylation of the primary amine with an alkyl halide having structure RD-J where J is a halogen or RE-J where J is a halogen, (c) acylation of the primary amine with an acyl group having the structure, C(=O) R7, (d) acylation of the primary amine with an acyl group having the structure, C(=O) CHR8NR RiO, (e) removal of the N-Alloc protecting group with the use OfPd(OAc)2, PPh3, and (nBu) SnH, (f) hydrolysis of all acetate groups to give the alcohol, (g) if the Rj is alkoxy, removal of the alkoxy group by mild base or acid hydrolysis to give the carboxylic acid derivative, (h) alkylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4 amino acid of the compound with an alkyl halide having structure R-J where J is a halogen, Rj-J where J is a halogen or Rc-J where J is a halogen (i) acylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4th amino acid of the compound with an acyl group having the structure, C{=0) R7, (j) acylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4 1 amino acid of the compound with an acyl group having the structure, C(=0) CHR NR R10, (k) reaction of the amino substituent on the amino-substitutcd sugar moiety of the 4* amino acid of the compound with an aldehyde or ketone followed by reductive amination of the resulting imine, (1) conversion of the acid moiety on the macrocyclic ring of the compound with substituted amide as defined by R , (m) phosgene reaction on primary alcohol or primary amine of the mono- sugar moiety of the 4 amino acid of the compound with the adjacent hydroxyl group, (n) a combination of (a), (e) and (f), (o) a combination of (a), (b), (e) and (f), (p) a combination of (a), (c), (e) and (f), (q) a combination of (a), (d), (e) and (f), (r) a combination of (a), (c), (e), (f) and (g), (s) a combination of (a), (c), (e) (f), (g) and (I), (t) a combination of (a), (d), (e), (f) and (g), (u) a combination of (a), (d), (e), (f), (g) and 0), (v) a combination of (a), (c), (e), (h) and (f), (w) a combination of (a), (d), (e), (h), and (f), (x) a combination of (a), (c), (e), (h), (f) and (g), (y) a combination of (a), (d), (e), (h), (f) and (g), (aa) a combination of (a), (d), (e), (h), (f), (g) and (1), (bb)a combination of (a), (c), (e), (i) and (f), (cc) a combination of (a), (d), (e), (i), and (f), (dd)a combination of (a), (c), (e), (i), (f) and (g), (ee) a combination of (a), (d), (e), (i), (f) and (g), (ff) a combination of (a), (c), (e), (i), (f), (g) and (1), (gg) a combination of (a), (d), (e), (i), (f), (g) and (1), (hh) a combination of (a), (c), (e), (j) and (f), (u) a combination of (a), (d), (e), (j), and (f), (Jj) a combmation of (a), (c), (e), (j), (f) and (g), (kk) a combination of (a), (d), (e), (|), (£) and (g), (11) a combmation of (a), (c), (e); (j), (f), (g) and (1), (mm) a combination of (a), (d), (e), 0), (f), (g) and (1), (nn) a combination of (a), (c), (e), (k) and (f), (oo)a combination of (a), (d), (e), (k), and (f), (pp)a combination of (a), (c), (e) (k), (f) and (g), (qq) a combmation of (a), (d), (e), (k), (f) and (g), (rr) a combmation of (a), (c), (e), (k), (f), (g) and (1), (ss) a combmation of (a), (d), (e), (k), (f), (g) and (i), compound having a foimula selected from the group consisting of wherein R, R1, R2,R3, R RA, RC» D RE, X Y and Z are as defined herein. [00112] In particular, the semi-synthetic glycopeptides described herein are made, for example, by modifying Compound A, Compound B, Compound H or Compound C scaffolds. These natural glycopeptide starting material is optionally unsubstituted or substituted at R4 with CH2NHCH2PO H2, or aminoloweralkyl as defined herein. [00113] Substitutions at R4 are introduced, for example, via Mannich reaction wherein the glycopeptide is treated with an amine and formaldehyde under basic conditions (for example, as described in The Journal of Antibiotics, Vol. 50, No. 6 p. 509-513). Pharmaceutical Compositions [00114] Pharmaceutical compositions described herein comprise a therapeutically effective amount of a compound described herein formulated together with one or more pharmaceutically acceptable carriers. As used herein, the term "pharmaceutically acceptable carrier" means non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as com starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants are also present in the composition, according to the judgment of the formulator. The pharmaceutical compositions described herein are administered to humans and other animals orally, rectally, parenterally, intracisternally, intravagmally, lnfraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray, or a liquid aerosol or dry powder formulation for inhalation. [00115] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs In addition to the active compounds, the liquid dosage forms optionally contain inert diluents such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, com, germ, ohve, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions optionally also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. [00116] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions are formulated using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation are optionally a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that are optionally employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are optionally employed as a solvent or suspending medium. For this purpose any bland fixed oil is optionally employed including synthetic mono- or diglyceπdes In addition, fatty acids such as oleic acid are used in the preparation of injectables. [00117] The injectable formulations are sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of steπle solid compositions which is dissolved or dispersed in sterile water or other sterile injectable medium prior to use [00118] In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drag from subcutaneous or intramuscular injection. This is accomplished, for example, by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, depends upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug n an oil vehicle Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release is optionally controlled. Examples of other biodegradable polymers include polyforthoesters) and ρoly(anhydrides) Depot injectable formulations are also prepared, for example, by entrapping the drug in liposomes or microemulsions which are compatible with body tissues, [00119] Compositions for rectal or vaginal administration are preferably suppositories which are optionally prepared by mixing the compounds described herein with suitable non-irritating excipients or earners such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound [00120] Solid dosage forms for oral administration mclude capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable exctpient or earner such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvmylpyrrohdinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar- agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, acetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form optionally compnses buffering agents, [00121] Solid compositions of a similar type are optionally employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. {00122] The solid dosage forms of tablets, dragees, capsules, pills, and granules are prepared, for example, with coatings and shells such as entenc coatings and other documented coatings. They optionally contain opacifying agents and also are of a composition that they release the active ingredients) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which are used include polymeric substances and waxes. [00123] Solid compositions of a similar type are optionally employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. [00124] The active compounds are optionally in micro-encapsulated form with one or more excipients as noted above The solid dosage forms of tablets, dragees, capsules, pills, and granules are optionally prepared with coatings and shells such as enteric coatings, release controlling coatings and other documented coatings. In such solid dosage forms the active compound is admixed, for example, with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms optionally comprise additional substances other than inert diluents, e.g , tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms optionally comprise buffering agents They optionally contain opacifying agents and are of a composition that they release the active ingredients) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which are used include polymeric substances and waxes. [00125] Dosage forms for topical or transdermal administration of a compound described herein include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable earner and any needed preservatives or buffers as required Ophthalmic formulations, ear drops, and the like are also contemplated. [00126] The ointments, pastes, creams and gels optionally contain, in addition to an active compound described herein, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof [00127] Compositions described herein are optionally formulated for delivery as a liquid aerosol or inhalable dry powder. Liquid aerosol formulations are nebulized, for example, predominantly into particle sizes that are delivered to the terminal and respiratory bronchioles where bacteria reside in patients with bronchial infections, such as chronic bronchitis and pneumonia. Pathogenic bacteria are commonly present throughout airways down to bronchi, bronchioli and lung parenchema, particularly in terminal and respiratory bronchioles. During exacerbation of infection, bacteria can also be present in alveoli. Liquid aerosol and inhalable dry powder formulations are preferably delivered throughout the endobronchial tree to the terminal bronchioles and eventually to the parenchymal tissue. (001281 Aerosolized formulations described herein are delivered, for example, using an aerosol forming device, such as a jet, vibrating porous plate or ultrasonic nebulizer, preferably selected to allow the formation of a aerosol particles having with a mass medium average diameter predominantly between 1 to 5 µ. Further, the formulation preferably has balanced osmolality ionic strength and chloride concentration, and the smallest aerosolizable volume able to deliver effective dose of the compounds described herein to the site of the infection. Additionally, the aerosolized formulation preferably does not impair negatively the functionality of the airways and does not cause undesirable side effects. [001291 Aerosolization devices suitable for administration of aerosol formulations described herein include, for example, jet, vibrating porous plate, ultrasonic nebulizers and energized dry powder inhalers, that are able to nebulize the formulation into aerosol particle size predominantly Ln the size range from 1-5 . Predominantly in this application means that at least 70% but preferably more than 90% of all generated aerosol particles are within 1-5 µ range. A jet nebulizer works by air pressure to break a liquid solution into aerosol droplets. Vibrating porous plate nebulizers work by using a sonic vacuum produced by a rapidly vibrating porous plate to extrude a solvent droplet through a porous plate. An ultrasonic nebulizer works by a piezoelectric crystal that shears a liquid into small aerosol droplets. A variety of suitable devices are available, including, for example, AeroNeb™ and AeroDose™ vibrating porous plate nebulizers (AeroGen, Inc., Sunnyvale, California), Sidestream® nebulizers (Medic-Aid Ltd., West Sussex, England), Pan LC® and Pari LC Star® jet nebulizers (Pari Respiratory Equipment, Inc., Richmond, Virginia), and Aerosonic™ (DeVilbiss Medizinische Produkte (Deutschland) GmbH, Heiden, Germany) and UltraAire® (OmroαHealthcare, Inc., Vernon Hills, Illinois) ultrasonic nebulizers. [00130] Compounds described herein are formulated, for example, for use as topical powders and sprays that contain, in addition to the compounds described herein, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays optionally contain customary propellents such as chlorofluorohydrocarbons. [00131] Transdermal patches have the added advantage of providing controlled delivery of a compound to the body, Such dosage forms made, for example, by dissolving or dispensing the compound in the proper medium. Absorption enhancers are optionally used to increase the flux of the compound across the skin. The rate is controlled, for example, by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel. [00132] According to the methods of treatment described herein, bacterial infections are treated or prevented in a patient such as a human or lower mammal by administering to the patient a therapeutically effective amount of a compound described herein, in such amounts and for such time as is necessary to achieve the desired result. By a "therapeutically effective amount" of a compound described herein is meant a sufficient amount of lie compound to treat bacterial infections, at a reasonable benefit/risk ratio applicable to any medical treatment. The total daily usage of the compounds and compositions described herein will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; (he age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment, drugs used in combination or coincidental with the specific compound employed; and like factors known in the medical arts. [00133] The total daily dose of the compounds described herein administered to a human or other mammal in single or in divided doses is in amounts, for example, from 0 0 1 to 50 mg/kg body weight or more usually from 0 1 to 25 mg/kg body weight Single dose compositions contain, for example, such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens described herein comprise administration to a patient in need of such treatment from about 10 mg to about 2000 mg of the compound(s) described herein per day in single or multiple doses. Abbreviations [00134| Abbreviations which may have been used in the descriptions of the schemes and the examples that follow are: AcOH for acetic acid; AIBN for azobisisobutyronitrile; nBu for normal butyl; (Boc)20 for di-terf-butyl dicarbonate, B SnH for tributyltin hydride; CDI for carbonyldiimidazole; DBU for l,8-diazabicyclo[5.4.0]undec-7- ene; DCC for dicyclohexyl carbodiunide; DCM for dichloromethane; DEAD for diethylazodicarboxylate; DMF for dimethylformamide; DIEA or DIPEA for N,N-diisoproρylethylamme; DMP for 2,2-dimethoxyρropane, DMSO for danethylsulfoxide (or methylsulfoxide); DPPA for diphenylphosphoryl azide; Et3N for triethylamine, EtOAc for ethyl acetate; Et2θ for diethyl ether; EtOH for ethanol, HOAc for acetic acid, HOSu for N-hydroxysuccimmide; LiHMDS or LiN(TMS)2 for lithium bis(trimethylsilyl)amide; MCPBA for metø-chloroperbenzoic acid; MeOH for methanol; MsCl for methanesulfonyl chloride; NaHMDS or NaN(TMS)2 for sodium bis(trimethylsilyl)amide; NMO for N-methylmorpholine N-oxide; SOCl2 for tbionyl chloride; PPTS for pyridium ^-toluene sulfonate; Pd(OAc) for palladium (II) acetate, PPh3 for tnphenylphosphine; Py for pyridine, TFA for tnfluoroacetic acid; TEA for π tnethylamine; THF for tetrahydroruran; TMSCl for trimethylsilyl chloride; TMSCF3 for trimethyl(t fluoromethyl)- silane; TPP for triphenylphosphine; TPAP for tetra-n-propylammonium permthenate; DMAP for 4-dιrαethylamino pyridine; TsOH for / -toluene sulfonic acid; MsOH for methanesulfonic acid: OMs for mesylate, OTs for tosylate; OTf for tnflate; Boc for tert-butoxycarbonyl; Fmoc for N-fluorenylmethoxycarbonyl; Su for succinimide; Ph for phenyl; HBPyU for 0-benzot πazol-l-yl-N,N,N',N',-bis(tetrameihylene)uroni ιιπi hexafhiorophosphate; PyBOP for benzotπazol-1-yloxytriρyrrolidinophosρhonium hexafluorophosphate; HATU for Λ Λ,JV' ΛT'-tetramethyl-0-(7- azabenzotriazol-l-yl)uranium hexafluorophosphate. Methicillin-Resistant Staphylococcus aureus [00135] Staphylococcus aureus (S. aureus), a spherical bacterium, is the most common cause of staph infections. S aureus has been known to cause a range of illnesses from minor skin infections, such a pimples, impetigo, boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome, abscesses, to life-threatening diseases such as pneumonia, meningitis, osteomyelitis endocarditis, toxic shock syndrome, and septicemia. Further, S. aureus is one of the most common causes of nosocomial infections, often causing postsurgical wound infections. [00136] Methicillin was introduced in the late 1950s to treat infections caused by penicillin-resistant S. aureus It has been reported previously that S. aureus isolates had acquired resistance to methicillin (methicillin-resistant S , aureus, MRSA). The methicillin resistance gene {mecA) encodes a methicillin-resistant penicillin-binding protein that is not present in susceptible strains. mecA is carried on a mobile genetic element, the staphylococcal cassette chromosome mec (SCCmec), of which four forms have been described that differ in size and genetic composition, The methicillin- resistant penicillin-binding protein allows for resistance to β-lactam antibiotics and obviates their clinical use during MRSA infections. [00137] In one aspect is a method for treating a subject having a resistant bacterium comprising administering to the subject a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomcr or prodrug thereof. In one embodiment, the bacterium is a Gram-positive bacteria. In another embodiment, the Gram-positive bacterium is S aureus. In further embodiment, the S. aureus is resistant or refractory to a beta-lactam antibiotic. In yet a further embodiment, the beta-lactam antibiotic belongs Io the class of penicillins. In a further embodiment, the beta-lactam antibiotic is methicillin. In yet another embodiment, the subject has a methicillin-resistant S. aureus bacteria. In one embodiment the beta-lactam antibiotic is flucloxacillin. In another embodiment is a method for treating a subject having a dicloxacillin-resistant bacteria comprising administering to the subject a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the subject is refractory to dicloxacillui Also disclosed herein is a method for treating a subject having a methicillin-resistant bacteria comprising administering a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the subject has been determined to have a methicillin-resistant bacteria. In one embodiment the subject is screened for methicillia-resistant bacteria. In another embodiment, the subject screening is performed through a nasal culture. In a further embodiment the methicillin-resistant bacteria is detected by swabbing the nostril(s) of die subject and isolating the bacteria In another embodiment, Real-time PCR and/or Quantitative PCR is employed to determine whether the subject has methicillin-resistant bacteria, [00138] In one embodiment is a method for treating a subject having a first-generation cephalosporin-resistatrt bacteria comprising administering a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the subject is refractory to a first-generation cephalosporin. In one embodiment, the bacteria is resistant to a first-generation cephalosporin. In a further embodiment, the bacteria i resistant to cefacetπle. In another embodiment, the bacteria is resistant to oefadroxil. In yet another embodiment (he bacteria is resistant to cefalexin. In one embodiment, the bacteria is resistant to cefaloglycin. In another embodiment, the bacteria is resistant to cefalonium In another embodiment, the bacteria is resistant to cefaloridine. In yet another embodiment, the bacteria is resistant to cefalotin. In a further embodiment, the bacteria is resistant to cefapuin In yet a further embodiment, the bacteria is resistant to cefatrizine. In one embodiment, the bacteria is resistant to cefazaflur. In another embodiment, the bacteria is resistant to cefazedone. In yet another embodiment, the bacteria is resistant to cefazolin. In a further embodiment, the bacteria is resistant to cefradine. Ih yet a further embodiment, the bacteπa is resistant to cefroxadine In one embodiment, the bacteria is resistant to ceftezole. [00139] In one embodiment is a method for treating a subject having a second-generation cephalosporin-resistant bacteria comprising administering a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the subject is refractory to a second-generation cephalosporin. In another embodiment, the bacteπa is resistant to a second- generation cephalosporin. In a further embodiment, the bacteria is resistant to cefaclor. In another embodiment, the bacteria is resistant to cefonicid. In yet another embodiment, the bacteria is resistant to cefprozil. In one embodiment, the bacteria is resistant to cefuroxime. In another embodiment, the bacteria is resistant to cefuzonam. In another embodiment, the bacteria is resistant to ceimetazoie. In yet another embodiment, the bacteria is resistant to cefotetan. In a further embodiment, the bacteria is resistant to cefoxitin. [00140] In one embodiment is a method for treating a subject having a third-generation cephalosporin-resistant bacteria comprising adπiinistering a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the subject is refractory to a third-generation cephalosporin. In another embodiment, the bacteria is resistant to a third-generation cephalosporin. In a further embodiment, the bacteria is resistant to cefcapene. In another embodiment, the bacteria is resistant to cefdaloxime. In yet another embodiment, the bacteria is resistant to cefdinir. In one embodiment, the bacteria is resistant to cefditoren. In another embodiment, the bacteria is resistant to cefixime. In another embodiment, the bacteria is resistant to cefinenoxime. In yet another embodiment, the bacteria is resistant to cefodizime. In a further embodiment, the bacteria is resistant to cefotaxime. In yet a further embodiment, the bacteria is resistant to cefpimizole. In one embodiment, the bacteria is resistant to cefpodoxime. In another embodiment, the bacteria is resistant to cefteram. In yet another embodiment, the bacteria is resistant to ceftibuten. In a further embodiment, the bacteria is resistant to ceftiorar. In yet a further embodiment, the bacteria is resistant to ceftiolene. In one embodiment, the bacteria is resistant to ceftizoxime. I Q another embodiment, the bacteria is resistant to ceftriaxone. In yet another embodiment, the bacteria is resistant to cefoperazone. In yet a further embodiment, the bacteria is resistant to ceftazidime. [00141] In one embodiment is a method for treating a subject having a fourth-generation cephalosporin-resistant bacteria comprising administering a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the subject is refractory to a fourth-generation cephalosporin. In another embodiment, the bacteria is resistant to a fourth- generation cephalosporin. In a further embodiment, the bacteria is resistant to cefclidine. In another embodiment, the bacteria is resistant to cefepime. In yet another embodiment, the bacteria is resistant to cefluprenam. In one embodiment, the bacteria is resistant to cefoselis. In another embodiment, the bacteria is resistant to cefozopraπ. In another embodiment, the bacteria is resistant to cefpirome. In yet another embodiment, the bacteria is refractory to cefquinome. [00142J In one embodiment is a method for treating a subject having a carbapenem-resistant bacteria comprising administering a compound of Formula (I) (XR) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the subject is refractory to a carbapenem. In another embodiment, the bacteria is resistant to a carbapenem. In a further embodiment, the bacteria is resistant to imipenem. In another embodiment, the bacteria is resistant to meropenem. In yet another embodiment, the bacteria is resistant to ertapenem. In one embodiment, the bacteria is resistant to faropenem. In another embodiment, the bacteria is resistant to doripenem. In another embodiment, the bacteria is resistant to panipenem. In yet another embodiment, the bacteria is resistant to biapenem. Vancomydn-Intermediate and Vancomyciπ-Resistant Staphylococcus aureus [0Θ143] Vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant staphylococcus aureus are specific types of antimicrobial-resistant Staph bacteria that are refractory to vancomycin treatment S. aureus isolates for which vancomycin MICs are 4-8 µg/mL are classified as vancomycin-intermediate and isolates for which vancomycin MICs are Sl6 µg/mL are classified as vancomycin-resistant (Clinical and Laboratory Standards Institute/NCCLS. Performance Standards for Antimicrobial Susceptibility Testing. Sixteenth informational supplement. M100-S16. Wayne, PA: CLSI, 2006). [00144] As used herein, the term "minimum inhibitory concentration" (MIC) refers to the lowest concentration of an antibiotic that is needed to inhibit growth of a bacterial isolate in vitro, A common method for determining the MIC of an antibiotic is to prepare several tubes containing serial dilutions of the antibiotic, that are then inoculated with the bacterial isolate of interest. The MIC of an antibiotic is determined from the tube with the lowest concentration that shows no turbidity (no growth). [00145] In one aspect is a method of treating a subject having a bacterial infection comprising administering to the subject a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the bacterial infection comprises a vancomycin- intermediate Staphylococcus aureus bacterium. In one embodiment, the vancomycin-intermediate Staphylococcus aureus bacterium has a MIC of between about 4 to about 8 µg/mL. In another embodiment, the vancomycin- intermediate Staphylococcus aureus bacterium has a MIC of about 4 µg/mL. In yet another embodiment, the vancomycin-intermediate Staphylococcus aureus bacterium has a MIC of about 5 µg/mL. In a further embodiment, the vancomycin-intermediate Staphylococcus aureus bacterium has a MIC of about 6 µg/mL. In yet a further embodiment, the vancomycin-intermediate Staphylococcus aureus bacterium has a MIC of about 7 µg/mL. In one embodiment, the vancomycin-intermediate Staphylococcus aureus bacterium has a MIC of about 8 µg/mL. [00146] In another aspect is a method of treating a subject having a bacterial infection comprising administering to the subject a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the bacterial infection comprises a vancomycin-resistant Staphylococcus aureus bacterium. In one embodiment, the vancomycin-resistant Staphylococcus aureus bacterium has a MIC of between about 16 µg/mL. In another embodiment, the vancomycin- resistant Staphylococcus aureus bacterium has a MIC of about > 16 µg/mL. In yet another embodiment, the vancomycin-resistant Staphylococcus aureus bacterium has a MIC of about 20 µg/mL. In a further embodiment, the vancomycin-resistant Staphylococcus aureus bacterium has a MIC of about 25 µg/mL. [00147] In one embodiment, conditions treated by the compounds described herein include, but are not limited to, endocarditis, osteomyelitis, neningitis, skin and skin structure infections, genitourinary tract infections, abscesses, and necrotizing infections. In another embodiment, the compounds disclosed herein are used to treat conditions, such as, but not limited to, diabetic foot infections, decubitus ulcers, bum infections, animal or human bite wound infections, synergistic-necrotizing gangrene, necrotizing fascilitis, intra-abdominal infection associated with breeching of the intestinal barrier, pelvic infection associated with breeching of the intestinal barrier, aspiration pneumonia, and post-operative wound infections. In another embodiment, the conditions listed herein are caused by, contain, or result in the presence of VISA and/or VRSA. Vancomycin-Resistant Enterococci [00148] Enterococci are bacteria that are normally present in the human intestines and in the female genital tract and are often found in the environment. These bacteria sometimes cause infections. I some cases, enterococci have become resistant to vancomycin (also known as vancomycin-resistant enterococci or VKE.) Common forms of resistance to vancomycin occur in enterococcal strains that involve the acquisition of a set of genes endoding proteins that direct peptidoglycan precursors to incorporate D-Ala-D-Lac instead of D-AIa-D-AIa. The six different types of vancomycin resistance shown by enterococcus are: Van-A, Van-B, Van-C, Van-D, Van-E and Van-F. In some cases, Van-A VEE is resistant to both vancomycin and tcicoplanrn, while in other cases, Van-B VRE is resistant to vancomycin but sensitive to teicoplanrn, m further cases Van-C is partly resistant to vancomycin, and sensitive to teicoplanin [00149] In one aspect, is a method of treating a subject having a vancomycin-resistant enterococci comprising administering to the subject a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the enterococci has developed resistance to vancomycin. In one embodiment, the subject has been previously treated with vancomycin for a sustained period of tune In another embodiment, the subject has been hospitalized In yet another embodiment, the subject has a weakened immune system such as patients in Intensive Care Units or in cancer or transplant wards In a further embodiment, the subject has undergone surgical procedures such as, for example, abdominal or chest surgery In yet a further embodiment, the subject has been colonized vith VRE In one embodiment, the subject has a medical device such that an infection has developed In another embodiment, the medical device is a urinary catheter or central intravenous (IV) catheter [00150] In another embodiment, is a method of treating a subject having a vancomycin-resistant enterococci comprising administering to the subject a compound of Formula (I) (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the enterococcus has Van-A resistance. [00151] In another embodiment, is a method of treating a subject having a vancomycin-resistant enterococci comprising administering to the subject a compound of Formula (I) - (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the enterococcus has Van-B resistance [00152] In another embodiment, is a method of treating a subject having a vancomycin-resistant enterococci comprising administering to the subject a compound of Formula (I) (XII) or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof wherein the enterococcus has Van-C resistance EXAMPLES [00153J The following examples provide details concerning the synthesis, properties and activities and applications of semi-synthetic glycopeptides descnbed herein. It should be understood the following s representative only Example 1 Synthesis of Compound £1} 0 I001S4J Vancomycin (30 g) was added slowly to a mixture solution (300 ml, TFA H2O = 9:1) at 1O C Then flie reaction mixture was stiired at 1O0C for 2hrs (with reaction progress checked by HPLC). The reaction mixture was quenched with 1500 ml cold diethyl ether, the precipitate was filtered and washed by ether several tunes, then dried under vacuum. The crude product was purified by reverse phase column (MeCN:H2O=10%~20%) to afford Compound £1} as a white solid (yield = 45%). Example 2 Synthesis of Compound £2] (21 [00155] Using a procedure similar to the preparation of Compound £1}, replacing vancomycin with desmethylvancomycm, Compound (2) is made Example 3 Synthesis of Compound £3) [00156] Using a procedure similar to the preparation of Compound £1), and replacing vancomycin with LY264826, Compound (31 is made. Example 4 Synthesis of Compound £4) 100157] Using a procedure similar to the preparation of Compound £1}, and replacing vancomycin with eremomycin, Compound ( is made. Example 5 Synthesis of Compound £51 [00158] Compound I (5.Og, 3.72 mmol) was dissolved in THF/ H2O (35 ml/ 35 ml). TEA (0.77 ml, 5.58 mtnol) was then added. The reaction mixture was cooled down to 15 0C and then (BoC) O (0.89 g 4.08 mmol) was added slowly. After the addition, the reaction mixture was allowed to be stirred at 15 0C for 7 hrs. It was concentrated and (he crude was purified by reverse phase column (MeCN:H 2O=l :5-3:10). 3g of Compound £5) was obtained as a white solid (yield = 60%). Example 6 Synthesis of Compound £6} [00159] Using a procedure similar to the preparation of Compound £51, and replacing Compound £11 with Compound £2], Compound (61 is made. Example 7 Synthesis of Compound £7} [00160] Using a procedure similar to the preparation of Compound , and replacing Compound £1] with Compound £3}, Compound is made. Example 8 Synthesis of Compound £8} [00161] Using a procedure similar to the preparation of Compound £SJ, and replacing Compound £1} with Compound £4}, Compound (8] is made. Example 9 Synthesis of Compound £9} m [00162] Using a procedure similar to the preparation of Compound }, and replacing Compound 1 with vancomycin, Compound {9 is made Example 10 Synthesis of Compound £10} [00163] Using a procedure similar to the preparation of Compound £5), and replacing Compound £1} with desmethylvancomycin Compound (1O] is made, Example 11 Synthesis of Compound £11] [00164] Compound £5] (Ig, 0.712 mmol) and 2-adamantylamine hydrochloride (0.4g, 2.1 mmol) were dissolved in anhydrous DMSO (12ml). DIEA was added the solution to adjust the pH of reaction mixture to 8. HATU (0.3g, 0.789 mmol) was then added in the presence of DIEA. Stirring was continued for about 1 hr, checking the progress of the reaction to completion by TLC. The resulting mixture was then added to 120 ml of water and filtered. The cake was washed for two times with water and dried in vacuum. Purification by running a normal phase silica column (MeOH: CH2Cl2 = 1:7-1:3) gave the Compound £11] as white solid (850 mg, yield = 77%). Example 12 Synthesis of Compound £12} [00165] Using a procedure similar to the preparation of Compound £11 , and replacing Compound £5] with Compound £6j, Compound (12} is made. Example 13 Synthesis of Compound (131 [00166] Using a procedure similar to the preparation of Compound £U], replacing Compound £5} with Compound £7), Compound (131 i s s,. Example 14 Synthesis of Compound (14) [00167] Using a procedure similar to the preparation of Compound fill and replacing Compound £5 with Compound £8], Compound (14} is made. Example 15 Synthesis of Compound £15) [00168] Using a procedure similar to the preparation of Compound £12], replacing Compound £5} with Compound fS , Compound (15} is made. Example 16 Synthesis of Compound (16) [00169] Using a procedure similar to the preparation of Compound (11). and replacing Compound £5] with Compound (10). Compound (16} is made. Example 17 Synthesis of Compound £171 0 [00170] To a suspension of Compound (11) (380 mg) in CH2Cl (4ml) at 0 C , was added TFA (0.5 ml) diopwise The reaction mixture was stirred at 0 0C for 1 hour and then at room temperature for another hour. The reaction was follow by HPLC until the analysis showed no starting material present. Ether (30 ml) was added and the forming solid was collected and washed with ether twice. The collected white solid was dπed and purified by preparative HPLC to yield Compound Q } as TFA salt Example 18 Synthesis of Compound {18} [00171] Using a procedure similar to the preparation of Compound (17), and replacing Compound {11} with Compound £12}, Compound (181 TFA salt is made. Example 19 Synthesis of Compound (19} [00172] Using a procedure similar to the preparation of Compound (17), and replacing Compound (11) with Compound 13 5 Compound (19} as TFA salt is made, Example 20 Synthesis of Compound 20} [00173] Using a procedure similar to the preparation of Compound {171, a replacing Compound (111 with Compound £14}, Compound QO} as TFA salt is made. Example 2 1 Synthesis of Compound {21} [00174] Using a procedure similar to the preparation of Compound £121, and replacing Compound (Ul with Compound (15), Compound (211 TFA salt is made. Example 22 Synthesis of Compound {221 [00175] Using a procedure similar to the preparation of Compound OH d replacing Compound £111 Compound (16). Compound (221 s TFA salt is made. Example 23 Synthesis of Compound (231 [00176] To Compound (111 (1.0 g, 0.65 mtnol) and DMAP (0.25 g, 2.0 mmol) in dry DMF (15 ml) at room temperature, was added slowly CsHi7NCO (0.20 g, 1.30 mmol) After stirring at room temperature for 15 hours, the reaction mixture was precipitated in ether and the solid was washed with water and collected to yield Compound (23) (1.0 g, 91% yield) as a white solid. Modification of conditions for the preparation of Compound (23) was conducted as follows. Compound (11) (100 mg) was azeotroped with toluene three times. This was dissolved in 1 ml dry DMF DBU (3.0 equivalent) in 1 ml dry DMF was added under argon atmosphere in an ice bath followed fay the addition of isocyanate CeHi7NCO (2,0 equivalent) m l ml DMF, The mixture was stirred at room temperature overnight The reaction was checked fore ompletion by HPLC-MS. The reaction was quenched by adding water, and then filtered, The cake was washed three times with water. The crude compound was purified by preparative HPLC to afford Compound (23). Example 24 Synthesis of Compound (24) [00177] Using a procedure similar to the preparation of Compound (23). and replacing Compound (U) with Compound f!2>. Compound (24J is made. Example 25 Synthesis of Compound £25) [00178] Using a procedure similar to the preparation of Compound , and replacing Compound £11) with Compound £13}, Compound (251 i . Example 26 Synthesis of Compound Q [00179] Using a procedure similar to the preparation of Compound £23J, and replacing Compound £111 i Compound £141, Compound (26J is made. Example 27 Synthesis of Compound £271 [00180] Using a procedure similar to the preparation of Compound 2 , and replacing Compound £111 with Compound (15). Compound (27} is made. Example 28 Synthesis of Compound £28} [00181] Using a procedure similar to the preparation of Compound (23). and replacing Compound fll) with Compound /JjQ, Compound S 1S m Example 29 Synthesis of Compound £29} 0 [00182] To a suspension of Compound £23] (1.0 g, 0.58 mtnol) in CH2Cl (16 ml) at 0 C, was added TFA (4 ml) dropwise The reaction mixture was stirred at 0 0C for 1 hour Ether (80 ml) was added and the forming solid was collected and washed th ether 3 times. The collected white solid was dried and purified by preparative HPLC to yield Compound (29) as TFA salt (150 mg, 15%) as a white solid. Preparation HPLC conditions' Eluent 65/35 of MeCN/H 2O (with 0. 1 % TFA); Flow rate- 10 ml/mm; Column size- 250* 22 mm; Retention tune approximately 10 mill. Example 30 Synthesis of Compound (30) [00183! Using a procedure similar to the preparation of Compound (29) . and replacing Compound 23 wilh Compound (24). Compound (3OJ as TFA salt is made. Example 31 Synthesis of Compound (31) [00184] Using a procedure similar to the preparation of Compound 2 ). and replacing Compound (23) with Compound {2.51, Compound (31] as TFA salt is made. Example 32 Synthesis of Compound (32) [00185] Using a procedure similar to the preparation of Compound (29). and replacing Compound (23) with Compound £|6][, Compound (32} as TFA salt is made. Example 33 Synthesis of Compound (33J [00186] Using a procedure similar to the preparation of Compound £291, n replacing Compound f23) with Compound (27) . Compound (331 F- salt is made. Example 34 Synthesis of Compound (34) [00187] Using a procedure similar to the preparation of Compound (29) . and replacing Compound (23) with Compound (28). Compound (3 as TFA salt is made. Example 35 Synthesis of Compound (35) [0018S] Using a procedure similar to the preparation of Compound (23). and reacting Compound (11) with the appropriate isocyanate or thioisocyanate (RB-NCO or RB-NCS), and treating the resulting product with TFA following the procedure as outlined in Example 29 to yield Compound as a TFA salt where Z is O or S and RB is loweralkyl, substituted loweralkyl, phenyl, pyridyl, substituted aryl or substituted heteroaryl is made. Example 36 Synthesis of Compound (36) [00189] Using a procedure similar to the preparation of Compound (23], and reacting Compound £12} with the appropriate isocyanatø or thioisocyanate (R B-NC0 or Rg-NCS), and treating the resulting product with TFA following the procedure as outlined in Example 29 to yield Compound (3 Example 37 Synthesis of Compound £321 [00190] Using a procedure similar to the preparation of Compound (23). and reacting Compound f!3) with the appropriate isocyanate or thioisocyanate (RB-NCO or RB-NCS), and treating the resulting product with TFA following the procedure as outlined in Example 29 to yield Compound (37} as a TFA salt where Z is O or S and RB is loweralkyl, substituted loweralkyl, phenyl, pyridyl, substituted aryl or substituted heteroaryl is made. Example 38 Synthesis of Compound (38) [00191] Using a procedure similar to the preparation of Compound (23}, and reacting Compound £14} with the appropriate isocyanate or thioisocyanate (RB-NCO or RB-NCS), and treating the resulting product with TFA following the procedure as outlined m Example 29 to yield Compound QSi as &TFA salt where Z is O or S and RBis loweralkyl, substituted loweralkyl, phenyl, pyπdyl, substituted aryl or substituted heteroaryl is made Example 39 Synthesis of Compound (39) [00192] Using a procedure similar to the preparation of Compound (23). and reacting Compound (15) with the appropriate isocyanate or thioisocyanate (RB-NCO or RB-NCS), and treating the resulting product with TFA following the procedure as outlined in Example 29 to yield Compound (391 a TFA salt where Z is O or S and RB IS loweralkyl, substituted loweralkyl, phenyl, pyridyl, substituted aryl or substituted heteroaryl is made. Example 40 Synthesis of Compound £40} [00193] Using a procedure similar to the preparation of Compound (73). and reacting Compound (16) with the appropriate isocyanate or thioisocyanate (R -NCO or RB-NCS), and treating the resulting product with TFA following the procedure as outlined in Example 29 to yield Compound (4(Q as a TFA salt where Z is O or S and RB is loweralkyl, substituted loweralkyl, phenyl, pyridyl, substituted aryl or substituted heteroaryl is made. Example 41 Synthesis of Compound (41} [00194] To a solution of Compound Jl (7 30 g, 5 59 mmol) dissolved into H O (28 mL) and THF (28 mL) was added Alloc-OSu (2.07 g, 11.18 mmol, 2 eq.) at room temperature. To the above mixture, DIPEA ( 1.4 mL) was added dropwise at room temperature (approx. 5 nun) After stirring at room temperature for 1.5 hour, the reaction mixture was then monitored by analytical HPLC until the reaction was complete. The volatile solvents were removed under reduced pressure, and the residual material was re-dissolved into MeOH (10 mL). This clear solution was poured slowly into ethyl ether (200 mL) with stirring. A mass of white precipitate formed rapidly 7.18 g of white solid Compound (41) was collected by filtration under vacuum Example 42 Synthesis of Compound (42) [00195] To a solution of Compound {41] (7. 18 g, 5.16 mmol) in DMF (5OmL) was added NaHCO3 (5.20 g, 61.9 mmol, 10 eq.) at room temperature. To the stirring suspension was added dropwise ally! bromide (6.25 g, 51.6 mmol, 12 eq ) at room temperature (approx, 10 mm) The reaction mixture was stirring at room temperature and followed by HPLC analysis until completion (approx. 24 hours). The un-dissolved inorganic solid was removed by filtration. The clear filtrate was poured slowly into ethyl ether (200 mL) to yield a syrup-hke residue, The upper solvents were removed by decantation. The residual syrup was dissolved into MeOH (20 mL) and was poured into ethyl ether again. The formed solid was collected by filtration under vacuum. This operation was repeated twice again. Finally, 6.79 g of Compound {42J was obtained as a white solid. Example 43 Synthesis of Compound {43} [00196] To a solution of Compound {421(1.43 g, 1.0 mmol) in DMF (5 mL) was added Cs2CO3 (1,14 g, 3.5 mmol) with stirring rapidly at room temperature. To the stirring suspension was added dropwise aliyl bromide (375 mg, 3,1 mmol) at room temperature within 30 min. After stirred at room temperature overnight, the undissolved solid was removed by filtration. The clear filtration was poured slowly into ethyl ether to form a mass of white solid, After standing for 30 min, the upper clear solvent was removes by decantation. The residual solid was re-dissolved into MeOH (20 mL) and was poured into ethyl ether again. The formed solid was collected by filtration under vacuum. This operation was repeated once again. 1.09 g of crude Compound 43 was collected by filtration as a white solid. Further purification conducted by preparative HPLC gave the pure Compound (43) . Separation column: ALL TIMA µ C18, 22mm LD. x 250mm, 5 m; Mobile phase: CH3CN/H2O=50/50; Pump flow rate: 10 ml/min. Example 44 Synthesis of Compound {44} [00197] To a solution of Compound 43Ϊ (3 g, 1.93 mmol) dissolved into deionized H2O (2OmL) and CH3CN (20 mL) was added phenyliodinc-bis-trifluoroacetate (1.78 g 2.5 eq.) at 0 0C, The reaction was warmed to room temperature naturally and stirred overnight. All solvents were removed under vacuum. The residual solid was washed with ether (3x30 mL). The further purification was conducted by a silica gel flash column chromatography (silica gel: 300-400 mesh; eluent: CH2Cl2/MeOH=80/20-»40/60). Compound 144) (1.2 g) was obtained as a yellowish solid, Example 45 Synthesis of Compound (45) [00198] To a mixture of Compound J[441 (152 mg, 0.10 mmol ) and pyridine (24 mg, 0.30 mmol) in dry DMF (0.5 ml) at room temperature under N2, was added slowly a solution of acetyl chloride (8 mg, 0.10 mmol) in dry DMF (0.5 ml). After stirring at room temperature for 1 hour, HPLC showed a new product formed with retention time of approximately 14 min. The reaction mixture was precipitated in ether and the forming solid was washed with ether ra and collected to yield Compound £451 ( 110 g» 71%) as a white solid. Example 46 Synthesis of Compound (46) [00199] To a mixture of Compound i451 ( 110 mg), Pd(OAc) 2 (22 mg, 0.10 mmol) and PPh 3 (105 mg, 0.40 mmol) in DMF / AcOH (1 ml / 1 ml) at room temperature, was added Bu3SnH (2.91 g, 10.0 mmol) in one shot. The reaction mixture was stirred at room temperature for 10 min. Ether was added and the forming solid was collected and washed with ether a few times until a white color was achieved. The collected white solid was dried and purified by preparative HPLC to yield Compound 46 as a TFA salt (7 mg, 7%). Preparative HPLC conditions: Eluent: 50 / 50 of MeCN / H2O (with 0.1% TFA); Flow rate: 10 ml/ min; Column size: 250*22 mm; Retention time: around 14.5 min. Example 47 Synthesis of Compound 47 [00200] To a solution of Compound £42) in CH2Cl2 (5 g, 3.5 mmol) was added dropwise pyridine (20 mL) and acetic anhydride (25mL) successively at room temperature with stirring rapidly. A catalytically amount of DMAP (500 mg) was added. The reaction was stirred at room temperature for 3 days. The reaction mixture was washed with brine (3*30 mL), dried on MgSO4, and condensed under reduced pressure to yield 5.0 g of crude Compound {47) as a yellowish solid. Further purification was conducted by a silica gel flash column chromatography (silica gel: 300- 400 mesh; eluent: CH2Cl3/MeOH=100/0->30/70) to yield 3.0 g of Compound £471 as an off-white solid. Example 48 Synthesis of Compound (4JQ [00201] To a solution of Compound {47J (3 g, 1.66 mmol} dissolved into deionized H2O (25 mL) and CH3CN (25 mL) was added phenyliodine-bis-triftuoroacetate (1.78 g, 2.5 eq.) at 0 0C. The reaction was warmed to room temperature naturally and stirred overnight. The volatile solvents were removed under vacuum. The residue was re- dissolved into CH Cl (50 mL). The organic phase was washed with brine (3*30 mL), dried over anhydrous Na SO and condensed to give the crude Compound (48). Further purification conducted by a silica gel flash chromatography (silica gel: 300-400 mesh; eluent: CH2Cl2MeOH= 100/0->40/60) to afford 2.6 g of Compound {48} as an off-white solid. Example 48 Synthesis of Compound (4g) [00202] To a stirring solution of Compound 481 (900 mg, 0.51 aimol) i DMF (10 mL) was added octanoic acid (73 mg, 1 eq.); HATU (385mg, 1 eq.), and DIPEA ( 1 mL) successively. After stirring for 50 min, the reaction mixture was poured into CH2CI2 (50 mL). The newly formed solution was washed with brine (3 30 mL), dried over anhydrous MgSO4 and condensed under reduced pressure to yield the crude Compound f49). Purification was conducted by preparative HPLC. Separation column: ALL TIMA C18, 22mm LD, 250mm, 5 µm; Mobile phase: CH3CN/H2O88/12; Pump flow rate: 10 mL/rnin. The crude was also purified by normal silica gel flash column chromatography (silica gel: 300-400 mesh; eluent: Hexanes/EtOAc = 50/50/ to 0/100). Example 50 Synthesis of Compound (50) [002Θ3] Using a similar procedure as the preparation of Compound (46), and replacing Compound (45) with Compound (49), Compound (50) was prepared. Example 5 1 Synthesis of Compound (51) [00204] To 0.10 mmol of Compound (50) in 5inL of methanol/water mixture (3:1) in a round bottom flask is added 1.1 mtnol of potassium carbonate. The mixture is stirred at room temperature for 20 hours yielding Compound (51). Example 52 Synthesis of Compound (52) [00205] Compound (11) (1 g, 0.649 mmol) was azeotroped with toluene 3 times and then dissolved in anhydrous pyridine. Mesitylenesulfonyl chloride (426 mg, 1.95 mmol) in 1 ml of anhydrous pyridine was added to the solution dropwise at 0 0C, and the mixture was kept stirring for 2 hour. The reaction mixture was poured into water and filtered. The solid was purified by flashing normal phase column (MeOH DCM=l/l(M/5) to give Compound (52) as a white solid (500 mg, yield =5 0%). LC-MS (ESI): 1020(MVl-BoC), Example 53 Synthesis of Compound (53) [00206] Using a procedure similar to the preparation of Compound {52}, and replacing Compound £11) with Compound £12}, Compound (53} is prepared. Example 54 Synthesis of Compound (54) [00207] A solution of Compound (52) (Ig, 0.581 nunol) and sodium azide (377mg, 5.81 mmol, lOeq.) in anhydrous DMF was heated to 70 0C overnight. The reaction mixture was cooled and added to water. The solid was filtered, washed with water, and purified by flashing normal phase column (MeOH/DCM =1/12-1/9) to give Compound (Sj) as a pale yellow solid (500 mg, yield = 50%). LC-MS (ESI): 1463(M H-I-BOcJ. Example 55 Synthesis of Compound (55) [00208] To a solution of Compound (5J) (1 g 0.639 mmol) in 5 ml THF containing a few drops of water was added n-Bu P (905 mg, 4.47 mmol). The mixture was heated to reflux overnight, then cooled to room temperature, and poured into water. The solid was filtered, washed with water, and purified by flashing reverse phase column (MeCN/ + H2O=l/9~l/3) to afford Compound (55) as a pale yellow solid (100 mg, yield 10%). LC-MS (ESI): 1537(M +!). Example 56 Synthesis of Compound (56) [00209] To a solution of Compound (55) (380 mg) in 2 ml of THF containing 10 drops of water was added di-tert butyl dicarbonate (1.05 eq) and TEA (2.0 eq). The mixture was stirred at room temperature for 5 hours. The reaction was checked for completion by HPLC-MS, The solvent was evaporated to afford Compound (56) upon purification byprep-HPLC. Example 57 Synthesis of Compound (57) [00210] Using Compound (56) (100 mg) was azeotroped with toluene for three times. It was the dissolved in 1 ml dry DMF. DBU (3.0 equivalent) in 1 ml dry DMF was added under argoαatmosphere ifl an ice bath followed by the addition of isocyanate C Hi7NCO (2.0 equivalent) in 1 ml DMF. The mixture was stirred at room temperature overnight. The reaction was checked for completion by HPLC-MS, The reaction was quenched by adding water, and then filled. The cake was washed three times with water. The crude compound was purified by preparative HPLC to afford Compound f57V Example 58 Synthesis of Compound (38) [00211] Compound 571 in 2 ml of TEA/DCM (I/I) was stirred for 1 hour in an ice-bath. The reaction was checked for completion by HPLC-MS. The solvent was removed under reduced pressure at 0 0C. The residue was washed with ether and filtered to give Compound (SgI as a TFA salt. Example 9 Synthesis of Compound (59) (3d\ [00212] Using a procedure similar to the preparation of Compound (45), and replacing Compound £441 with Compound £55), Compound (59) is made. Example 0 Synthesis of Compound (60) [00213] Using a procedure simitar to the preparation of Compound (29}, and replacing Compound £23} with Compound £59}, Compound (60} is prepared Example 6 1 Synthesis of various carboxamide glycopeptides derivatives (61-66) [00214] Using a similar to the preparation of Compound £11-161, and replacing 2-adamantylamine hydrochloride with RiJ-NH hydrochloride and reacting it with Compound £5-10}, Compound ( i'iiill wherein R [ is as defined, is prepared. Example 61 Synthesis of various carbosamide glycopeptides derivatives 67-72 [00215] Following the synthetic methodology as Example 23 followed with the removal of the protecting group with a procedure similar to Example 30. Compound (67-22). wherein R 3 is as defined, is prepared from Compound (61- 66). Example 62 Synthesis of Compound (73 & 74) [00216] Using a procedure similar to the preparation of Compound (23), and replacing C8Hi7NCO with (1- isocyanatoethyl)benzene, Compound (73) and also Compound (74) were made. Example 63 Synthesis of Compound (75) [00217] Using a procedure similar to the preparation of Compound (29), and replacing Compound (23) with Compound (73), Compound (75) was prepared as a TFA salt. Example 64 Synthesis of Compound (76) [00218] Using a procedure similar to the preparation of Compound (29), and replacing Compound (23) with Compound (74), Compound (76) was prepared as a TFA salt. Example 65 Synthesis of Compound (72) [90219] To 0.10 mmol of Compound (48) in 10 mL of allyl alcohol in a round bottom flask is added 1.1 mmol of potassium carbonate. The mixture is stirred at room temperature for 20 hours yielding Compound (77), Example Synthesis of Compound (78) SISH [00220] Using a procedure similar to the preparation of Compound (23) and replacing Compound (11) with Compound (77), Compound (78) is made. Example 67 Synthesis of Compound (79) (79) [00221] Using a procedure similar to the preparation of Compound (23) and replacing Compound (11) with Compound (77) and C3Hj7NCO with C H17NCS, Compound (79) is made. Example 68 Synthesis of Compound (M) [00222] Using a procedure similar to the preparation of Compound (46) and replacing Compound (45) with Compound (78), Compound (80) is prepared. Example 69 Synthesis of Compound (81) (B1) [0O223] Using a procedure similar to the preparation of Compound (46) and replacing Compound (45) with Compound (79), Compound (81) is made. Example 70 Synthesis of Compound (82) f821 [00224] Using a procedure similar to the preparation of Compound (23) and replacing Compound (11) with Compound (77) and C8H 17NCO with RBNCO, and subjecting the resulted product with deprotection methodology as in Example 46, Compound (82) is prepared. Example 7 1 Synthesis of Compound (83 & 84) [00225] Using a procedure similar to the preparation of Compound (11) as m Example 11. replacing Compound (5) wtth Compound £51_or 80), Compound (83J and Compound (84) is prepared Example 72 Synthesis of Compound (85) [00226] Using a procedure similar to the preparation of Compound (23) (example 23), replacing C H17NCO with reagent CeHi3NCO, nitrogen protected Boc-85 was produced. Subsequent de-protection of Boc-85 by treatment with TFA wtth a procedure similar to the preparation of Compound (29) (example 29), Compound (85) was prepared as a TFA salt. Example 73 Synthesis of Compound (86) (00227] Using a procedure similar to the preparation of Compound (85) (example 72), and replacing reagent Q H 1 NCO with reagent C7Hi5NCO, Compound (86) was prepared as a TFA salt. Example 74 Synthesis of Compounds (S]), (88), (89), (90) and (91) [0022Sj Using a procedure similar to the preparation of Compound (85) (example 72), and replacing reagent CeHnNCO with reagents l-butyl-4-isoeyanatobenzene, l-methoxy-4- isocyanatobenzene, l-ethoxy-4- isocyanatobenzetie, l-butoxy-4- isocyanatobenzene and 2-adamantyl lsocyaαate, Compounds (87), (88), (89), (90) and (Pl), respectively, were prepared as a TFA salt. LC-MS (M+ + 1): Compound (8J): 1613.5; Compound (88): 1587,5; Compound (82): 1601.5; Compound («HJ): 1629.5; Compound (M): 1615.6. Example 75 Synthesis of Compounds (92), (93), (94), (25), (96) a n (£7) [00229] Using a procedure similar to the preparation of Compound (11) (example 11), and replacing reagent 2- adamamylamine with N 1, N 1-dimethy]propane-l,3-diamine, 1-methylpiperazine, cyclopropanamine, proρan-2-amine, O-methylhydroxylamine and 2-methylρroρan-2-amine, Compounds (92), (93), (94), (95), (9 ) and (97), respectively, were prepared. Example 76 Synthesis of Compounds (98) and (99) [00230] Using a procedure similar to the preparation of Compound (23) (example 23), replacing Compound QJ) with Compound (92), and substituting the isocyanate C8Hi7NCO with various isocyanate, nitrogen protected acylureas were prepared. Subsequent de-protection of acylamides by treatment with TFA with a procedure similar to the preparation of Compound (29) (example 29), Compounds (98) and (22) were prepared as a TFA salt. LC-MS (M++ 1): Compound (98): 1544.6; Compound (99): 1516.5, Example 77 Synthesis of Compounds (100) and (101) [00231] Using a procedure similar to the preparation of Compound (23) (example 23), replacing Compound Ql) with Compound (93), and substituting the isocyanate C8Hi7NCO with various isocyanates, nitrogen protected acylureas were prepared. Subsequent de-protection of acylamides by treatment with TFA with a procedure similar to the preparation of Compound (29) (example 29). Compounds (10J) and (101) were prepared as a TFA salt. LC-MS (M+ + 1): Compound QQOJ: 1514.5; Compound QOl): 1542,5. Example 78 Synthesis of Compounds (102) and (IpJ) [00232] Using a procedure similar to the preparation of Compound (23) (example 23), replacing Compound (11) with Compound (94), and substituting the isocyanate CgHi 7NCO with various isocyanates, nitrogen protected acylureas were prepared. Subsequent de-protection of acylamides by treatment with TFA with a procedure similar to the preparation of Compound (29) (example 29), Compounds f!02) and (103) were prepared as a TFA salt. LC-MS (M + + 1): Compound (102): 1471.5; Compound (103): 1499.5. Example 79 Synthesis of Compound flO4) [00233] Using a procedure similar to the preparation of Compound (23) (example 23), replacing Compound (IVj with Compound (95), and substituting the isocyanate C8H i NCO with C 6H i3NCO, nitrogen protected acylureas were prepared. Subsequent de-protection of acylamides by treatment with TFA with a procedure similar to the preparation of Compound (29) (example 29), Compound (104) was prepared as a TFA salt. LC-MS (M+ + 1): 1473.5. Synthesis of Compounds (105) and (106) [00234] Using a procedure similar to the preparation of Compound (23) (example 23), replacing Compound (U) with Compound (96), and substituting the isocyanate C8H i7NCO with various isocyanates, nitrogen protected acymreas were prepared. Subsequent de-protection of acylamides by treatment with TFA with a procedure similar to Ihe preparation of Compound (29) (example 29), Compounds (105) and (106) were prepared as a TFA salt LC-MS (M+ + 1): Compound (105): 1461 5 ; Compound QM): 1489.5. Example 81 Synthesis of Compounds (107) and (108) [00235] Using a procedure similar to the preparation of Compound (23) (example 23), replacing Compound (11) with Compound (97), and substituting the isocyanate C8Hi7NCO with various isocyanates, nitrogen protected acylureas were prepared. Subsequent de-protection of acylamides by treatment with TFA with a procedure similar to the preparation of Compound (29) (example 29), Compounds (107) and (IQj) were prepared as a TFA salt. LC-MS (M *+ 1): Compound (107): 1515.5.; Compound (108):1478.5, Example 82 Synthesis of te/*-butyl 2-(4-isocyanatophenoxy)ethyl(methyl)carbamate [00236] To a mixture 2-(methylamino) ethanol (5.0 g, 66.5 mmol) in 15ml of ethyl acetate was added a solution of (BoC)2O (14.5 g, 66.5 mmol) in 5 mi of ethyl acetate dropwise with cooling in an ice bath The resulting mixture was stirred at room temperature for 2 hours, and the solvent was removed by evaporation under reduced pressure. The residue was dissolved in ethyl acetate, washed with water, dried over Na SO4 and filtered. After removing the solvent, the crude tert-butyl 2-hydroxyethyl(methyl)carbamate was used without further purification for the next reaction (10.5 g, 90%) A solution of diisopropyl azodicarboxylate (5.22 g, 25.9 mmol) in 5 ml of THF was added dropwise to a solution of 4-nitryl phenol (3.0 g, 2 1 56 mmol), tert-butyl 2-hydroxyethyl(methyl)carbamate (4.53 g, 25.9 minol) and triphenylphosphine (6.78 g, 25.9 mtnol) in 60 ml of THF with ice-bath cooling under nitrogen atmosphere. The resulting mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure by evaporation. The residue was mixed with ether and filtered. The filtrate was concentrated and purified by flashing silica gel column (Petroleum ether/Ethyl acetate=10/l~8/l) to afford the intermediate /ert-butyl methyl(2-(4-nitrophenoxy)ethyl)carbamate (2.48 g. 39%) To a solution of this intermediate -butyl methyl(2-(4- nitrophenoxy)ethyl)carbamate (2.48 g, 8.4 mmol) in methanol was added Pd/C under hydrogen atmosphere. The mixture was heated to 50 0C for 1 hour, and then cooled down to room temperature and filtered. The filtrate was concentrated to give the crude -butyl 2-(4-amuiophenoxy)ethyl(methyl)carbamate which was used without further purification for the next reaction (2.10 g, 95%). To a solution of tπphosgene (206 mg, 0.695 mmol) in DCM was added tert-butyl 2-(4-aminophenoxy)ethyl(methyl)carbamate (500 mg, 1.88 mmol) with ice-bath cooling followed by dropwise addition of TEA (380 mg, 3,76 mmol). After that, the mixture was stirred at room temperature for 2 hours. Tbe solvent was removed under reduced pressure without heating. The residue mixed with ether and filtered, The filtrate was concentrated to give tert-butyl 2-(4-isocyanatophenoxy)ethyl(methyI)carbamate (500 mg). Example 83 Synthesis of tert-biityl 2-(4-isocyanato ρhenoxy)cthyl(ethyL)carbamate [00237] Using a procedure similar to the preparation of /erf-butyl 2-(4-isocyanatophenoxy)ethyl(methyl)carbamate (example 82), replacing 2-(methylamino)ethanol with 2-(etfiylamino)ethanol, the isocyanate, -butyl 2-(4- isocyanatophenoxy)ethyl(ethyl)carbamate were made. Example 84 Synthesis of Compounds QOJ), (110), (111), (112), (113), OH), O!_D (116), (IVJ), (118), (119), (120), (121). (122) and (123) [00238| Using a procedure similar to the preparation of Compound (57) as in example 57 and replacing the isocyanate C8H17 NCO with an appropriate isocyanate, Compounds QO?), (110), (111), (112), (113), (114), (115), (116). (117). (118), (112), (120), (121), (122J and (123) were made. Example 85 Synthesis of tert-butyl 2-(4-!socyanatopheuoxy)ethj1(propyl)carbamate [00239] Using a procedure similar to the preparation of r -butyl 2-(4-isocyanatoρhenoxy)ethyl(methyl)carbamate (example 82), replacing 2-(methylamino)ethanol with 2-(propylamino)ethanol, the isocyanate, tert-b tyl 2-(A- isocyanatophenoxy)ethyl(ρropyl)carbamate is made. Example 86 Synthesis of Compounds (124), Q2£), (126), (127), (12®, 0 2) , (131), (132), (133J, (134), (135), (136), (137) and (138) [00240] Using a procedure similar to the preparation of Compound (58) as in example 58 and replacing Compound (22) with Compounds (109), (no), oil), 012), OM), (IM), (US, (IM), 012). (11S)- 012). (12PJ, O2D, (!22I and (123), the acyhirea derivatives Compounds (124), (125), (126), (127), (128), (129), (130), (131), (1 2), 133 . (134) . (1351. GM), (137) and (138) were made as TFA salts. Example 87 Alternate Synthesis of Compound (21) [00241] To a solution of vancomycin hydrochloride (100.0 g) in DMSO (800 mL) was added 2-adamantylamine hydrochloride (20.0 g), DIPEA (35.0 g) and HATU (28.1 g) with staring at ambient temperature. The reaction mixture was stirred overnight, Analytical HPLC showed the reaction completed. DMSO was removed under vacuum The residue was subjected to purification by reverse phase silica gel column chromatography (C18 silica gel, CH CN-H2O:5%-30%). The collected fraction was condensed to give Compound (21) (45 g) as a white powder. Example 88 Synthesis of Compound (139) [00242] To a solution of Compound <2J) (35.0 g) in 1,4-dioxane (50 mL) and water (50 mL) was added Fmoc-OSu (P-fluorenylmethyloxycarbonyl-O-succinimide) ( 11.0 g) with stirring at room temperature. After the reaction mixture was stirred at ambient temperature for 2 hr, the solvent was removed under reduced pressure. The resulting solid was collected by filtration under vacuum and was purified by silica gel column chromatography (silica gel, MeOH- CH2C12; 10%-20%) to give Compound (139), (20 g) as a white solid. Example 89 Synthesis of Compound (140) [00243] Using a procedure similar to the preparation of Compound (57) as in Example 57 and replacing Compound σ (56) with Compound (139), and isocysnate C H 17NCO with l-is cyanato-4-methoxybenzene, Compound (140) was made Example 90 Alternate Synthesis of Compound (141) [00244] Compound (140) obtained from Example 89 was dissolved into DMF (9 mL) and then diethylamine (3 eq.) was added at ambient temperature. After stirring at room temperature for 2 hr, the reaction mixture was poured into ether. The formed solid was applied on preparative HPLC to give Compound ("1411. Example 9 1 Synthesis of Compound (142) & (143) [00245] Using a procedure provided in Examples 89 and 90 in the preparation of Compound (141) and replacing 1- isocyanato-4-methoxybenzene with l-isocyanato-4-butoxybenzene or l-isocyanato-4-ethoxybenzene, Compound (142) and Compound (143) were prepared, respectively. Example 92 Synthesis of Compound (144) 044) [00246] Using a procedure similar to the preparation of Compound (140) as in Example 89 and replacing 1- isocyanato-4-methoxybenzene with l-isocyanato-4-(2-(9-fhiorenyhnethyloxycarbonylamino)ethoxy)benzene , Compound (144) is prepared. Example 93 Synthesis of Compound (145) U-IS) [002471 Using a procedure similar to the preparation of Compound (141) as in Example 90 and replacing Compound (140) with Compound (144), Compound (145) is made. Example 94 Synthesis of Compounds (146), (147), (148), (IM) a < (ISO) [00248] Using a procedure similar to the preparation of Compound (140) as in Example 9 and replacing 1- isocyanato-4-methoxybenzene with other appropriate isocyanates , Compounds (146). (147), (148) (148) and (150) are prepared. Example 95 Synthesis of Compounds (151), (152), (153), (154) and (155) [00249] Using a procedure similar to the preparation of Compound (141) as in Example 90 and replacing Compound (140) with Compounds (146), (147), (148), QiS), and (150), Compounds (151), Q52), (153), Q54), and (J55) are prepared, respectively. Example 96 Synthesis of Compounds (156), (157), Q5S), QSS), (160) and (161) [00250] Using a procedure provided in Examples 84 and 86 in the preparation of various acylurea derivatives such as Compounds (124), and using appropriate isocyanates, acylurea Compounds (156), (157), (158). (158). (160). and (161) are prepared. Example 97 Synthesis of Compound (162) f162> [00251] To a solution of mixture of N-(2-aminoethyl)-4-(pentyloxy)benzenesulfonamide (151 mg, 0.53 mmol) and Compound (139) (1 g, 0.53 mmol) in acetonitrile (30 mL) and water (30 mL) was added 37% aqueous formaldehyde (1,2 g, 14.8 mmol) and acetic acid (640 mg, 10.7 mmol) at room temperature. The reaction mixture was stirred for an additional 20 hr at room temperature. The volatile solvents were removed under reduced pressure. The formed solid was collected by filtration and washed with EtOAc. The crude product was dissolved into DMF (5 mL). After diethylamine (22 mg) was added, the reaction mixture was stirred at room temperature for 40 minutes and then was poured into ether (20 mL). The formed solid was applied on preparative HPLC to give Compound (162) as a white powder. Example 98 Synthesis of Compound Q 63) M63) [00252] Using a procedure similar to the preparation of Compound (162) as in Example 97 and replacing Compound (139) with Compound (146) . Compound (163) is made. Example 99 Synthesis of Compounds (164), (165), Q ) (167), (168) and (169) [00253] Using a procedure similar to the preparation of Compound (162) as in Example 97 and replacing Compound (139) with Compound (146). and N-(2-aminoethyl)-4-(pentyloxy)benzenesulfonannde with various aminoalkyl sulfonamide, Compounds M ) (165), (166). (167). (168) and (169) are prepared. Example IQO Synthesis of Compound (170) [00254] Using a procedure similar to the preparation of Compound (162) as in Example 97 and replacing Compound (139) with Compound (140). and Compound (170) is made. Example IQI Synthesis of Compounds (171), (172), (173), (VU), (175) (176), (177), (178), (179), (180) and (181) [00255] Using a procedure similar to the preparation of Compound (162) as in Example 97 and replacing Compound fl3j» with Compound (140). and N-(2-aminoethyl)-4-(ρentyloxy)benzenesulfonamide with various aminoalkyl sulfonamide or aminoalkylacetamide, Compounds (171), (172), (173), (124), (125) (176), (177), (12S), (172), (180) and (181) are prepared. Antibacterial Evaluation [00256] Antibacterial activity in vitro is investigated by broth microdilution method in Meuller-Hinton broth as recommended by NCCLS. All strains tested are clinical isolates either sensitive or resistant to natural glycopeptides. MIC values were determined using the CLSI-recommended broth microdilution procedure (Clinical and Laboratory Standards Institute, Methods for Dilution Antimicrobial Susceptibility Testsfor Bacteria That Grow Aerobically; Approved Standard-Seventh Edition.). Automated liquid handlers (Multidrop 384, Labsystems, Helsinki, Finland, Biomek 2000 and Multimek 96, Beckman Coulter, Fullerton CA) were used to conduct serial dilutions and liquid transfers. Biological data SA SA SA SE SE EFC EFC E FCM EFCM S PNE S PYO 100 757 2012 835 831 101 848 750 752 1195 712 29 2 1 1 1 0.5 1 2 0.5 2 0.12 0.12 75 4 2 4 2 1 2 2 0.5 2 1 0.25 76 2 2 4 1 1 2 8 0 5 8 0.25 0.06 SA 100 = Staphylococcus aureus 100 (MSSA); SA 757 = Staphylococcus aureus 757 (MRSA); SA2012 = Staphylococcus aureus 2012 (VISA); SE 835 = Staphylococcus epidemidis 835 (MSSE); SE 831 Staphylococcus epidermidis 831 (MRSE); EFC 101 = Enterococcusfaecalis 101 (vancomycin sensitive); EFC 848 = Enterococcus faecalis 848 (VRE); EFCM 750 = Enterococcusfaecium 750 (vancomycin sensitive); EFCM 752 = Enterococcus faecium 752 (VRE); SPNE 1195 = Streptococcus pneumoniae 1195 (penicillin sensitive); SPYO 712 = Streptococcuspyogenes 111 (penicillin sensitive). Clinical Trial of the Safety and Efficacy of Compounds of Formula (I) - (XII) in Patients with C. Difficile- Associated Diarrhea [00257] Purpose: This study aims to determine the safety and efficacy of glycopeptide compounds presented herein for the treatment of symptoms of C. difficile-associated diarrhea and lowering the risk of repeat episodes of diarrhea. The compounds are evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study-related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is approximately 10 weeks. Patients: Eligible subjects will be men and women 18 years and older. Criteria: Inclusion Criteria: Be at least 18 years old; Have active mild to moderate C . difficile- Associated Diarrhea (CDAD); Be able to tolerate oral medication; Not be pregnant or breast-feeding; and Sign and date an informed consent form. [00258] Study Design: This is a randomized, double-blind, active control study of the efficacy, safety, and tolerability of a compound of Formula (I) (XII) in patients with C. difficile-associated diarrhea. Clinical Trial Comparing a Compound of Formula (T) - (XII) with Vancomycin for the Treatment of MRSA Osteomyleiris [0O259J Purpose: This study aims to determine the efficacy of glycopeptide compounds presented herein as compared to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. Patients: Eligible subjects will be men and women 18 years and older. Criteria: Inclusion Criteria: Culture-proven MRSA, obtained in operating room or sterile biopsy procedure from bone site. The infection and sampling site is either within the bone or a deep soft-tissue site that is contiguous with bone; OR radiographic abnormality consistent with osteomyelitis in conjunction with a positive blood culture for MRSA; Surgical debridement of infection site, as needed, Subj ect is capable of providing written informed consent, and Subject capable of receiving outpatient parenteral therapy for 12 weeks Exclusion Criteria' Hypersensitivity to a compound of Formula (I) - (XII) or vancomycin, S. aureus resistant to compound of Formula (I) - (XII) or vancomycin, Osteomyelitis that develops directly from a chronic, open wound, Polymicrobial culture (the only exception is if coagulase-negative staphylococcus is present in the culture and the clinical assessment is that it is a contaminant); Subject has a positive pregnancy test at study enrollment; Baseline renal or hepatic insufficiency that would preclude administration of study drugs, Active injection drug use without safe conditions to administer intravenous antibiotics for 3 months, and Anticipated use of antibiotics for greater than 14 days for an infection other than osteomyelitis [00260] Study Design' This is a randomized, open-label, active control, efficacy trial comparing vancomycin with a compound of Formula (I) - (XII) for the treatment of MRSA Osteomyelitis Clinical Trial Evaluating a Compound of Formula (I) (XH) in Selected Serious Infections Caused by Vancom) cin-Resistant Eiiierococcus (VRE) [00261] Purpose: This study aims to determine the safety and efficacy of a compound of Formula (I) - (XII) in the treatment of selected serious infections caused by VRE Patients Eligible subjects will be men and women 18 years and older Criteria: Inclusion Criteria Isolation of one of the following multi-antibiotic resistant bacteria vancomycin-resistant Enterococcus faecium, vancomycin-resistant Enterococcus faecalis atone or as part of a polymicrobial infection, and Have a confirmed diagnosis of a serious infection (eg, bacteremia [unless due to an excluded infection], complicated intra-abdominal infection, complicated skin and skin structure infection, or pneumonia) requiring administration of intravenous (IV) antibiotic therapy. Exclusion Criteria Subjects with any concomitant condition or taking any concomitant medication that, in the opinion of the investigator, could preclude an evaluation of a response or make it unlikely that the contemplated course of therapy or follow-up assessment will be completed or that will substantially increase the risk associated with the subject's participation m this study Anticipated length of antibiotic therapy less than 7 days [00262] Study Design: This is a randomized, double-blind, safety and efficacy study of a compound of Formula (I) - (XII) in the treatment of selected seπous infections caused by VRE, [00263] Although the foregoing embodiments have been described in some detail for purposes of clarity of understanding, it will be apparent that m some embodiments, certain changes and modifications are practiced within the scope of the appended claims It should be noted that there are many alternative ways of implementing both the processes and compositions described herein. Accordingly, the present embodiments are to be considered as illustrative and not restrictive, and the aspects described herein are not to be limited to the details given herein, but in some embodiments are modified within the scope and equivalents of the appended claims. CLAIMS WHAT IS CLAIMED IS: 1. A compound having a structure selected from the group consisting of Formulas (I-XII): wherein, RA is selected from the group consisting of a) hydrogen, b) methyl, c) Cr-Cn-alkyl; R 1 and R2 are each independently selected from the group consisting of a) hydrogen, b) d-Cn-alkyl, c) Ci-Ci 2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cr Cj2-alkoxy, (d) Ci-C -alkoxy- C r C3-aIkoxy, (e) amino, (f) C[-Ci 2-alkylamino, (g) Ci-Ci 2-dialkylamino, (h) alkenyl, (i) alkynyl, (j) Ci-C 1 -thioalkoxy, d) Ci-Ci 2-alkyl substituted with aryl, e) Ci-Ci 2-aLkyl substituted with substituted aryl, f) C]-Ci 2-alkyl substituted with heteroaryl, g) C]-Ci 2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j) heterocycloalkyl, or R and R2 taken together with the atom to which they are attached form a substituted heteroaryl or 3-10 membered heterocycloalkyl ring which optionally contains one to two hetero functionalities selected from the group consisting of-O-, -N-, -NH, -N(C 1-C -SUyI)-, -N(aryl)-, -N(aryl- Ci-C 5- alkyl-)-, -N(substituted-aryl- Cr C3-alkyl-)-, -N(heteroaryl)-, -N(heteroaryl- Cr C6-aIkyl-)-, - N(substituted-heteroaryl- Ci-Cs-alkyl-)-, and -S- or S(O) - wherein n is 1 or 2 and the 3-10 11 membered heterocycloalkyl ring is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, 00 Cj-C 3-alkoxy, (d) Q-Ca-alkoxy-Cj-Cj-alkoxy, (e) OXO, (0 Cr C3-alkyl, (g) halo-C r C3-alkyl, (h) Ci-Cj-alkoxy-C r C3-alkyI, and ) C(=O) R D C(=O) CH RgNRgRiowherein R8, R i consisting of hydrogen, ioweralkyi, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R and R] or R and Rio taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) C,-C 3-alkoxy, (d) Ci-C r alkoxy-Ci-C 3-alkoxy, (e) oxo, (f) C r C3-alkyl, (g) halo-Ci-C aLkyl, (h) Ci-Cj-alkoxy-Ci-Cj-alkyl; R7 is selected from the group consisting of a) hydrogen, b) CrC 12-alkyl, ) Ci-Ci 2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-Ci 2-alkoxy, (d) C 1-C 3-EiIkOXy-C 1-C 3-UIkOXy, (e) amino, (fj CrC^-alkylamino, (g) Cj-C -dialkylamino, (h) alkenyl, (i) alkynyl, (j) C|-C 12 -thioalkoxy, d) CrC 12-alkyl substituted with aryl, e) CrCi2-alkyl substituted with substituted aryl, ) Ci-Ci2-alkyl substituted with heteroaryl, g) CpC^-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j) heterocycloalkyl, k) Ci-Ci2-alkylamino; X is selected from the group consisting of ) hydrogen, (2) chlorine; Y is selected from the group consisting of (D oxygen, (2) NRi, wherein Ri is as previously defined; Z is selected from the group consisting of (1) oxygen, (2) sulfur; R is selected from the group consisting of (1) hydrogen, (2) cycloalkyl, (3) cycloalkenyl, (4) d-C^-alkyl, (5) C]-Ci2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cr C12-alkoxy, (d) Cr C3-alkoxy- Ci-C3-aikoxy, (e) -COORs wherein R is hydrogen or loweralkyl, (f) -C(O)NR R wherein R5 is as previously defined and R is hydrogen or loweralkyl, (g) amino, (h) NR R wherein R3 and R6 are as previously defined, or R5 and R are taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (i) halogen, (ii) hydroxy, (in) Ci-C3-alkoxy, (iv) Ci-C3-alkoxy-CI-C3-alkoxy, (v) oxo, (vi) Ci-C -alkyl, (vii) halo-CrC -alkyl, and (viii) CrCs-alkoxy-Ci-Cu-alkyl, (i) aryl, (j) substituted aryl, (k) heteroaryl, (1) substituted heteroaryl, (m) mercapto, (n) Ci-Ci2-thioaJkoxy, (6) C(=O)O R11, wherein Rn is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, (7) C(=O)N Rii Ri ,wherein Rn is as previously defined and R 1 is hydrogen, loweralkyl, substituted loweraikyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or Rn and R 12 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cr Cr alkoxy, (d) CrCs-alkoxy-Ci-Cj-alkoxy, (e) oxo, (f) d-dralkyl, (g) substituted loweralkyl, (h) halo-Cr C12-alkyl, (i) amino, (j) alkylamino, (k) dtalkylamuio, and (1) Cr C3-alkoxy-Cr C12-alkyl, or R and its connected oxygen atom taken together is halogen; R3 is selected from the group consisting of (D OH, (2) 1-adamantanamtno, (3) 2-adatnantanamino, (4) 3-amino-l-adamantanamino, (5) l-amino-3-adamantanamino, (6) 3-lo\reraIkyIamino-l-adamantanamino, (7) l-loweralkyIamino-3-adamantanamino, (8) ammo (9) NRnRu wherein Ru and R are each independently selected from the group consisting of hydrogen, loweralkyl, substituted loweralkyl, cycloalkyl, substituted cycloalkyl, aminoloweralky! wherera the amino portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalky!, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy or R and Ri4 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring, which s optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-C3-alkoxy, (d) Ci-Cs-alkoxy-CrCj-alkoxy, (e) 0x0, (f) Q-Cu-alkyl, (g) substituted loweralkyl, (h) halo-Ci-C, 2-alkyl, (1) amino, (j) alkylamino, (k) dialkylamino, and (1) C -C -alkoxy-C C -alkyl R4 selected from the group consisting of (1) wherein m is 1to 6 and R 1 is H or loweralkyl, (2) CH2NH- CHR15 -(CH 2VCONHSO RB, wherein p is 0 to 6 and R is H or loweralkyl, (3) CH2NH- CHR15 -(CH2VCOOH, wherein p is 0 to 6 and R is H or loweralkyl, (4) CH 2NRF-CHRI 5-(CH 2VNRGSO 2RB, wherein q is 2 to 4 and Ri5 is H or loweralkyl, RF and R0 are independently hydrogen, lower alkyl or taken together represents a -CH - , (5) H, (6) CH2NHCH2PO3H2, (7) aminoloweralkyl wherein the amino portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy; RB is selected from the group consisting of a) aryl, b) CrCralkyl, c) Ci-Cij-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-Ciralkoxy, (d) Cr C3-alkoxy- Cr C3-alkoxy, (e) amino, (f) CrCi 2-alkyIamino, (h) alkenyl, (i) alkynyl, (j) Ci-C]2-thioalkoxy, d) C -C -alkyl substituted with aryl, ) CrC^-alkyl substituted with substituted aryl, f) C]-Ci2-alkyl substituted with heteroaryl, g) Ci-Ci2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) heteroaryl, j) heterocycloalkyl, k) aryl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cx-Cu-alkoxy, (d) CrCt-alkoxy- Ci-C -alkoxy, (e) amino, (f) amino-Ci-C -alkoxy, (g) Cr Ci2-alkylamino, (h) Ci-C -alfcylamino- Ci-C -alkoxy, (i) CpC -dialkylamino, (]) Ci-C]2-diallcylamino- Cj-Cg-alkoxy, (k) alkenyl, (D alkynyl, (m) CpCirthioalkoxy, (n) C,-C, 2-aIkyl, 1) heteroaryl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cr Ci2-alkoxy, (d) Cr C6-alkoxy- CrC -alkoxy, (e) amino, (f> amino-Ci-C -alkoxy, (g) C^C^-alkylamino, (h) Ci-C^-alkylamino- C[-C -alkoxy, (i) Ci-Cn-dialkylamino, (J) CrCn-dialkylamino- Cr C6-alkoxy, (k) alkenyl, 0) alkynyl, (m) Cr Ci -thioalkoxy, (n) Cr C,2-alkyl; Rc is each selected from the group consisting of a) hydrogen, b) C1-C12-alkyl, c) Ci-Ciralkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-Ci -alkoxy, (d) Cr C3-alkoxy- Cr C3-alkoxy, (e) amino, (f) Ci-Ci2-alkylamino, (g) C -C!2-dialkylamino, (h) alkenyl, (i) alkynyl, (J) Cj-C -thioalkoxy, C -C, d) 1 12-alkyl substituted with aryl, e) Ci-Ci -alkyl substituted with substituted aryl, f) Ci-Ci 2-alkyl substituted with heteroaryl, g) Ci-Ci 2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j) heterocycloalkyl, k) C(=O) R7 wherein R7 is previously defined, 1) C(=O) CHR NR Riowherein Rg, R and Rio are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R and R oor R9 and Ri taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-C 3-alkoxy, (d) Cr C3-alkoxy-C r C -alkoxy, (e) 0x0, (0 Ci-Cralkyi, (g) halo-Ci-Qralkyl, (h) Cr C3-alkoxy-Ci-C 3-alkyl; RD and RE are each independently selected from the group consisting of a) hydrogen, b) Cr C 12-alkyl, c) Ci-Ci 2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) CpC -alkoxy, (d) Cr C3-alkoxy- Ci-C -alkoxy, (e) amino, (f) Ci-Ci 2-alkylamino, (g) Ci-Ci 2-dialkylamino, (h) alkenyi, (i) alkynyl, (j) C,-Ci 2-thioalkoxy, d) Cr C 12-alkyl substituted with aryl, ) C1-C 12 -alkyl substituted with substituted aryl, f) Ci-Ci -alkyl substituted with heteroaryl, g) C -C12-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j) heterocycloalkyl, or RD and REtaken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyl ring which optionally contains one to two hetero functionalities selected from the group consisting of -O-, -N-, -NH, -N(C r C6-alkyl)-, -N(aryl)-, -N(aryl- C r C6-alkyl-)-, - N(substituted-aryl- Cr C -alkyl-)-, -N{heteroaryl)-, -N(heteroaryl- Cr C -alkyl-)-, -N(substituted- heteroaryl- Ct-C^-alkyl-)-, and -S- or S(O)n- wherein n is 1 or 2 and the 3-10 membered heterocycloalkyl ring is optionally substituted with one or more substiruents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) C -C3-alkoxy, (d) Cr C3-alkoxy-Ci-C 3-alkoxy, (e) oxo, (f) C r C3-alkyl, (g) halo-d -C -alkyl, (h) Cr C3-alkoxy-C r C3-alkyl, and k) C(=O) R7 wherein R is previously defined, 1) C(=O) CH RsNR^Rio wherein Rg, R9 and Rio are each independently selected from a group consisting of hydrogen, lowβralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R and Ri0 or R and R 10 taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (C) Ci-C3-alkoxy, (d) Cj-C3-alkoxy-Cr C3-alkoxy, (e) oxo, (f) CrC 3-alkyl, (g) halo-CrC 3-alkyl, (h) Q-Cs-alkoxy-Cj-Cj-alkyl, m) C(=O) CH R8NR R7 wherein R7, R8 and R9 are as previously defined; or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof. 2. The compound of claim 1, wherein the compound has the Formula I or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 3. The compound of claim 1, wherein the compound has the Formula II or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1 4. The compound of claim 1, wherein the compound has the Formula in or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1 5. The compound of claim 1, wherein the compound has the Formula IV or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 6. The compound of claim 1, wherein the compound has the Formula V or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 7. The compound of claim 1, wherein the compound has the Formula VI or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 8. The compound of claim 1, wherein the compound has the Formula VII or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 9. The compound of claim 1, wherein the compound has the Formula VIII or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 10. The compound of claim 1, wherein the compound has the Formula IX or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 11. The compound of claim 1, wherein the compound has the Formula X or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 12. The compound of claim 1, wherein the compound has the Formula XI or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 13. The compound of claim 1, wherein the compound has the Formula XII or a pharmaceutically acceptable salt, ester, solvate, alkylated quaternary ammonium salt, stereoisomer, tautomer or prodrug thereof, wherein R, etc. have the meanings defined in claim 1. 14. The compound of claim 2, wherein RA is methyl and R4 is hydrogen. 15. The compound of claim 2, wherein RA is hydrogen and R4 s hydrogen. 16. The compound of claim 3, wherein RA is hydrogen, and R4 is hydrogen. 17. The compound of claim 3, wherein RA is methyl and R4 is hydrogen. 18. The compound of claim 4, wherein RA is methyl and R is hydrogen. 19. The compound of claim 4, wherein RA is hydrogen and R4 is hydrogen. 20. The compound of claim 5, wherein RA is methyl and R4 is hydrogen. 2 1. The compound of claim 5, wherein RA IS hydrogen and R is hydrogen. 22 The compound of claim 6, wherein X is chlorine and R4 is hydrogen. 23. The compound of claim 6, wherein X is hydrogen and R4 is hydrogen 24. The compound of claim 7, wherein RA is methyl and R4 is hydrogen. 25. The compound of claim 7, wherein RA is hydrogen, and R4 is hydrogen. 26. The compound of claim 8, wherein RA is methyl and R4 is hydrogen. 27. The compound of claim S, wherein RA is hydrogen, and R is hydrogen 28. The compound of claim 9, wherein RA is methyl and R is hydrogen. 29 The compound of claim 9, wherein RA is hydrogen, and R4 is hydrogen. 30. The compound of claim 10, wherein RA is methyl and R4 is hydrogen. 3 1 The compound of claim 10, wherein R A is hydrogen, and R is hydrogen 32 The compound of claim 11, wherem X is chlorine and R is hydrogen. 33. The compound of claim 11, wherem X is hydrogen and R4 is hydrogen. 34 The compound of claim 12, wherein RA s methyl and R4 is hydrogen. 35. The compound of claim 12, wherem RA is hydrogen, and R4 is hydrogen 36. The compound of claim 13, wherein RA IS methyl and R4 is hydrogen. 37. The compound of claim 13, wherein RA IS hydrogen, and R is hydrogen 38 The compound of claim 1, wherem RA is methyl and R4 is CH2KHCH2PO3H2. 39. The compound of claim 1, wherem RA is hydrogen and R4 is CH2NHCH2PO3H2 40. The compound of any one of claims 14-39 wherein R3 is each selected from the group consisting of (1) OH (2) 1-adamantanamino, (3) 2-adamantanamino, (4) -amino-l -adarnantanamiπo, (5) l-anώ io-3-adamantanamino, (6) 3-bweralkylamino-l-adamantanamino, (7) l-loweralkylamino-3-adamantariamino, (8) ammo (9) NRi 3Ri4 wherein R and R 14 are each independently selected from the group consisting of hydrogen, loweralkyl, substituted loweralkyl, cycloalkyl, substituted cycloalkyl, armnoloweralkyl wherein the amino portion of the aminoloweralkyl group is further substituted with unsubstituted or substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, arylaryl, alkoxy, aryloxy, substituted alkoxy, and substituted aryloxy or Ru and Rf4 together with the atom to which they are attached form a 3-10 membered heterocycloalkyl πng, which is optionally substituted with one or more substrtuentø independently selected from the group consisting of (a) halogen, (b) hydroxy, (c) C -C3-alkoxy, (d) Ci-C -alkoxy-Cr C -alkoxy, (e) oxo, (f) C,-C I2-alkyl, (g) substituted loweralkyl, (h) halo-Cr Ci2-alkyl, (i) ammo, (j) alkylamino, (k) dialkylamino and (1) Ci-C3-alkoxy-Ci-Ci2-alkyl. 4 1, The compound of any one of claims 14-23, 34, 35, 38 and 39 wherein RB is each selected from the group consisting of a) aryl, b) C,-C t2-alkyl, c) Ci-Ci 2-alkyl substituted with one or more substituenis selected from the group consisting of (a) halogen, (b) hydroxy, (c) Cr C]r alkoxy, (d) Cr C3-alkoxy- Ci-C3-alkoxy, (e) amino, (f) C -Ci2-alkylamino, (g) Ci-Ci2-dialkylamino, (h) alkenyl, (i) alkynyl, 0) Q-Qrthioalkoxy, ) Ci-Ci2-alkyl substituted with aryl, e) Ci-Ci 2-alkyl substituted with substituted aryl, f) CpC -alkyl substituted with heteroaryl, B) Ci-C 12 -alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) heteroaryl, j) heterocycloatkyl, k) substituted aryl, 1) substituted heteroaryl. 42. The compound of any one of claims 24-33, 36, 37, 38 and 39 wherein RD and RE are each independently selected from the group consisting of a) hydrogen, b) Cr C12-alkyl, c) Ci-Cn-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-C 2-alkoxy, (d) Cr C3-alkoxy- Cr C3-alkoxy, (e) amino, (f) Cr Ci2-alkylamino, (g) Ci-Cj2-dialkylamuio, (h) alkenyl, (i) alkynyl, 0) Ci-Ci2-1hioalkoxy, d) Ci-Ci -alkyl substituted with aryl, e) CpC -alkyl substituted with substituted aiyl, f) Cr Ci2-alkyl substituted with heteroaryl, g) Ci-C -alkyl substituted with substituted heteroaryl, h) cycloalkyl, l) cycloalkenyl, j) heterocycloalkyl, or R D and RE taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl nng which optionally contains one to two hetero functionalities selected from the group consisting of-O-, -N-, -NH, -N(C,-C -alkyl)-, -N(aryl)-, -N(aryl- Cr C -alkyl-)-, - N(substituted-aryl- Cr CValkyl-)-, -N(heteroaryl)-, -N(heteroaryl- Cr C6-alkyl-)-, -N(substituted- heteroaryl- Q-Q-alkyl-)-, and -S- or S(O)n- wherein n is 1 or 2 and the 3-10 membered heterocycloalkyl ring is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-C3-alkoxy, (d) C C -alkoxy-d -C -alkoxy, (e) oxo, (f) C-Q-alkyl, (g) halo-CrCj-allcyl, (h) Cr C3-alkoxy-Cr C3-alkyl, and k) C(=O) R7 wherem R is previously defined. 1) C(=O) CH R8NR RiOwherein R , R9 and Ri0 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryi, substituted aryl, heteroaryl or substituted heteroaryl, or R and R] or R and Rio taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) C1-C -alkoxy, (d) Q-Cj-alkoxy-Q-Cralkoxy, (e) oxo, (f) Cr C3-alkyl, (g) halo-Ci-Cj-alkyl, (h) Cr C3-alkoxy-Ci-C3-alkyl, m) C(=O) CH R8NR9R7 wherein R7 R and R are as previously defined. 43. The compound of any one of claims 14 and 15 wherein R is each selected from the group consisting of (1) hydrogen, (2) cycloalkyl, (3) cycloalkenyl, (4) C,-C 12-alkyl, (5) Cr C12-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) C -C12-alkoxy, (d) Cr C3-alkoxy- Ci-C3-alkoxy, (e) -COORs wherein R5 is hydrogen or loweralkyl, (f) -C(O)NR5R6 wherein R5 is as previously defined and R is hydrogen or loweralkyl, (g) amino, (h) -NRsR 6 wherein R5 and R6 are as previously defined, or R5 and R5 are taken together with the atom to which they are attached form a 3- 10 membered heterocycloalkyi ring which is optionally substituted with one or more substituents independently selected from the group consisting of (i) halogen, (ii) hydroxy, (iii) Cr C -alkoxy, (iv) Ci-C3-a]koxy-Ci-Cj-alkoxy, (v) oxo, (Vi) C r C 12 -alkyl, (vn) halo-C r C ,2-a]kyl, and (vin) C 1 C3-EiIkOXy-C1-Clr alkyl, (i) aryl, 0 ) substituted aryl, (k) heteroaryl, (1) substituted heteroaryl, (m) mercapto, (n) Ci-Cj 2-tbioalkoxy, (6) C(=O)O Rn, wherein R n is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, (7) C(=O)N R n R]2, wherein Rn is as previously defined and R f is hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or Rn and R i together with the atom to which they are attached form a 3-10 membered heterocycloalkyl πng, which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxy, (c) C]-C 3-alkoxy, (e) oxo, (f) C1-C 12-EIkVl, (g) substituted loweralkyl, (h) halo-C r C i -alkyl, (i) ammo, (j) alkylamino, (k) dialkylamino, and (1) C.-Cj-alkoxy-Ci-Qa-alkyl, or R and its connected oxygen atom taken together is halogen. 44. The compound of any one of claims 30-33 wherein R is each selected from the group consisting of a) hydrogen, b) C,-C 12-alkyl, c) C[-Ci2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-C 12 -alkoxy, (d) CrCralkoxy- CrC 3-alkoxy, (e) amino, (f) Cr Ci2-alkyIamino, (g) Cr Ci2-diaIkylamino, (h) alkenyl, (i) alkynyl, d) Ci-Cn-alkyl substituted with aryl, e) Ci-C 1 -alkyl substituted with substituted aryl, f) Ci-Cij-alkyl substituted with heteroaryl, g) Ci-Ci2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j) heterocycloalkyl, k) C(=O) R7 wherein R is previously defined, 1) C(=O) CHR R9 and Ri0 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R and Ri0 or R and R taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Cr C3-alkoxy, (d) CL-C3-alkoxy-Ci-C3-alkoxy, (e) oxo, (f) Ci-Ca-alkyi, (g) hab-d-Cs-alkyl, (h) Cr Cr alkoxy-Cr C3-alkyl. 45. The compound of any one of claims 16- 19 and 26-29 wherein R1 and R2 are each independently selected from the group consisting of a) hydrogen, b) Cr C12-alkyl, c) Ci-Ci2-alkyl substituted with one or more substituents selected from the group consisting of (a) halogen, (b) hydroxy, (c) Ci-Ci2-alkoxy, (d) C,-C -alkoxy- C 1-C3-EiIkOXy, (e) amino, (f) C|-Ci 2'alkylamino, (g) C r C i2-dialkylamino, (h) aikenyl, (i) aikynyl, Ci) C r C 12-thioalkoxy, d) Ci-C 12-alkyl substituted with aryl, e) C]-Ci 2-alkyl substituted with substituted aryl, f) C]-Ci 2-aIkyl substituted with heteroaryl, g) C]-Ci 2-alkyl substituted with substituted heteroaryl, h) cycloalkyl, i) cycloalkenyl, j) heterocycloalkyl, or R 1 and R2 taken together with the atom to which they are attached form a substituted heteroaryl or 3-10 membered heterocycloalkyl ring which optionally contains one to two hetero functionalities selected from the group consisting of-O-, -N-, -NH, -N(C,-C 6-alkyl)-, -N(aryl)-, -N(aryl- C 1-C6- alkyl-)-, -N(substituted-aryl- C]-Cθ-alkyl-)-, -N(heteroaryl)-, -N(heteroaryl- C r C6-alkyl-)-, - N(substituted-heteroaryl- Cr C -alkyl-)-, and -S- or S(O) n- wherein n is 1 or 2 and the 3-10 membered heterocycloalkyl ring is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-Cj-alkoxy, (e) 0x0, (f) C-Cralkyl, (g) halo-C r C3-alkyl, (h) C r C3-alkoxy-C r Cr alkyl, and k) C(=O) R7, 1) C(=O) CH RgNRsRiowhereJn R , R9 and R 0 are each independently selected from a group consisting of hydrogen, loweralkyl, substituted loweralkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl, or R g and R or R and R ]0 taken together with the atom to which they are attached form a 3-10 membered heterocycloalkyl ring which is optionally substituted with one or more substituents independently selected from the group consisting of (a) halogen, (b) hydroxyl, (c) Ci-C3-alkoxy, (d) CrQs-alkoxy-Q-Cs-alkoxy, (e) oxo, (f) d-Cralkyl, (g) halo-Cj-Cj-alfcyl, (h) CrCj-alkoxy-Ci-Cs-alkyl. 46. The compound of any one of claims 14-23, 34, 35, 38 and 39 wherein Z is each selected from the group consisting of oxygen and sulfur. 47. A compound selected from the group consisting of: 48. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any of claims 1 to 47, together with a pharmaceutically acceptable carrier, diluent or excipient. 49. A method of treating a mammal in need of such treatment comprising administering to the mammal an antibacterial effective amount of a compound of any of claims 1to 47 together with a pharmaceutically acceptable carrier, diluent or excipient. 50. A method of making a compound of Formula I-V and XI in claim 1, comprising: modifying a compound from the group consisting of Formulas i, ii, iii, iv and v, wherein R AIS hydrogen or methyl, X is chlorine or hydrogen, R3 is alkoxy, 2-adamantanamino, or loweralkylannno as defined herein, or R4 is hydrogen or properly protected CHJNHCH 2PO H 2, or Boc- aminoloweralkyl as defined herein, by a technique selected from the group consisting of, rd (a) acylation of the primary amide group of the 3 amino acid asparagine with an RB-isocyanate or RB-thioisocyanate in the presence of a base such as dimethylaminopyndme and the like, (b) removal of the Boc protecting group with mild acid such as trifluoroacetic acid, (c) if the R3 is alkoxy, removal of the alkoxy group by mild base or acid hydrolysis to give the carboxylic acid derivative, (d) reduction of the azide function to an amine, (e) alkylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4th amino acid of the compound with an alkyl hahde having structure Ri-J where J is a halogen or R -J where J s a halogen (f) acylation of the primary alcohol of the mono-sugar or the amino substituent on the ammo- substituted sugar moiety of the 4th ammo acid of the compound with an acyl group having the structure, C(=O) R7, (g) acylation of the primary alcohol of the mono-sugar or the ammo substituent on the amino- substituted sugar moiety of the 4 amino acid of the compound with an acyl group having the structure, C(=O) CHR8NR9R10, (h) reaction of the ammo substituent on the amino-substituted sugar moiety of the 4th ammo acid of the compound with an aldehyde or ketone followed by reductive animation of the resulting lmine, (i) conversion of the acid moiety on the macrocychc ring of the compound with substituted amide as defined by R3, {]) phosgene reaction on primary alcohol or primary amine of the mono- sugar moiety of the 4th amino acid of the compound with the adjacent hydroxyl group, (k) dipolar cycloaddition of the azide with alkyne to form 1,2,3-tnzole, (1) a combination of (a) and (b), (m) a combination of (a), (b) and (c), (n) a combination of (a), (c), (i) and (b), (o) a combination of (a), (e), and (b), (p) a combination of (a), (f) and (b), (q) a combination of (a), (g) and (b), (r) a combination of (a), (h) and (b), (s) a combination of (a), (d) and (b), (t) a combination of (a), (d), (c) and (b), (u) a combination of (a), (c), (l), (d) and (b), (v) a combination of (a), (c), (d) and (b), (w) a combination of (a), (c), (i), (dj, (e) and (b), (x) a combination of (a), (c), (i), (d), (f) and (b), (y) a combination of (a), (c), (l), (d), (g) and (b), (z) a combination of (a), (c), (i), (d), (h) and (b), (aa) a combination of (a), (c), (d), (e) and (b), (bb) a combination of (a), (c), (d), (f) and (b), (cc) a combination of (a), (c), (d), (g) and (b), (dd) a combination of (a), (c), (d), (h) and (b), (ee) a combination of (a), (j), and (b), (ff) a combination of (a), O). (c), (0 and (b), (gg) a combination of (a), (d), (j), and (b), (hh) a combination of (a), (d), (j), (c), (i) and (b), (ii) a combination of (a), (k), and (b), OJ) a combination of (a), (k), (c), (i) and (b), compound having a formula selected from the group consisting of: wherein R, R1, R2, Rj, R4,R ., RB, RC, , Y and Z are as defined herein. 51. A method of making a compound of Formula VI-X and XII in claim 1, comprising: modifying a compound from the group consisting of Formulas vi, vϋ , viii, ix and x, wherein RA is hydrogen or methyl, X is chlorine or hydrogen, Rj is alkoxy, 2-adamantanarnino, or loweralkylamino as defined herein, or R4 is hydrogen or properly protected CH NHCH PO H2, or Boc- amiaoloweralkyl as defined herein, by a technique selected from the group consisting of, (a) Hofmann degradation of the primary amide group of the 3rd amino acid asparagine with phenyliodine-bis-trifluoroacetate to give the primary amine, (b) alkylation of the primary amine with an alkyl halide having structure RD-J where J is a halogen or RE-J where J is a halogen, (c) acylation of the primary amine with an acyl group having the structure, C(=O) R7, (d) acylation of the primary amine with an acyl group having the structure, C(=O) (e) removal of the N-Alloc protecting group with the use OfPd(OAc) , PPh3, and (nBu)3SnH, (f) hydrolysis of all acetate groups to give the alcohol, (g) if the R3 is alkoxy, removal of the alkoxy group by mild base or acid hydrolysis to give the carboxylic acid derivative, (h) alkylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4th amino acid of the compound with an alkyl halide having structure R-J where J is a halogen, RpJ where J is a halogen or R -J where J is a halogen (i) acylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substituted sugar moiety of the 4th amino acid of the compound with an acyl group having the structure, C(=O) R7, (J) acylation of the primary alcohol of the mono-sugar or the amino substituent on the amino- substitυted sugar moiety of the 4t amino acid of the compound with an acyl group having the structure, C(=O) CHR3MR9Ri0, (k) reaction of the amino substitueat on the amino-substituted sugar moiety of the 4th amino acid of the compound with an aldehyde or ketone followed by reductive amination of the resulting rmine, (1) conversion of the acid moiety on the macrocyclic ring of the compound with substituted amide as defined by R3, (m) phosgene reaction on primary alcohol or primary amine of the mono- sugar moiety of the 4 ammo acid of the compound with the adjacent hydroxyl group, (n) a combination of (a), (e) and (f), (o) a combination of (a), (b), (e) and (f), (p) a combination of (a), (c), (e) and (f), (q) a combination of (a), (d), (e) and (f), (r) a combination of (a), (c), (e), (f) and (g), (s) a combination of (a), (c), (e), (f), (g) and (1), (t) a combination of (a), (d), (e), (f) and (g), (u) a combination of (a), (d), (e), (f), (g) and (1), (v) a combination of (a), (c), (e), (h) and (f), (w) a combination of (a), (d), (e), (h), and (f), (x) a combination of (a), (c), (e), (h), (f) and (g), (y) a combination of (a), (d), (e), (h), (f) and (g), (z) a combination of (a), (c), (e), (h), (f), (g) and (1), (aa) a combination of (a), (d), (e), (h), (f), (g) and (1), (bb) a combination of (a), (c), (e), (1) and (f), (cc) a combination of (a), (d), (e), (1), and (f), (dd) a combination of (a), (c), (e), (1), (f) and (g), (ee) a combination of (a), (d), (e), (i), (f) and (g), (ff> a combination of (a), (c), (e), (1), (f), (g) and (1), (gg) a combination of (a), (d), (e), (1), (f), (g) and (1), (hh) a combination of (a), (c), (e), Q) and (f), (li) a combination of (a), (d), (e), (j), and (f), Oj) a combination of (a), (c), (e), (j), (f) and (g), (kk) a combination of (a), (d), (e), 0), (f) and (g), (U) a combination of (a), (c), (e), 0), (f), (g) and (1), (mm) a combination of (a), (d), (e), (]), (f), (g) and (I) (nn)a combination of (a), (c), (e), (k) and (f), (00) a combination of (a), (d), (e), (k), and (fj, (pp) a combination of (a), (c), (e), (k), (f) and (g), (qq) a combination of (a), (d), (e), (k), (f) and (g), (rr) a combination of (a), (c), (e), (k), (f), (g) and (1), (ss) a combination of (a), (d), (e), (k), (f), wherein R, Ri, R2, R , R4, RA, Rc, R D> E , Y d Z are as defined herein. INTERNATIONAL SEARCH REPORT International application No PCT/US2008/085716 A. CLASSIFICATION OF SUBJECT MATTER CO1C 235/00(2006. 01)i According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 8 C07K, A61K, C07C Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) e-KIPASS, GOOGLE SCHOLAR C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No US 7074760 B2(LTNSELL, M S ET AL ) 11 July 2006 1-47, 50, 51 See formula II, examples 1-5, claims 1-10 US 2003-008812 A1(CHRISTENSEN, B G ET AL ) 09 January 2003 1-47, 50, 51 See formula I, table 1, examples, claims 1-21 US 2004-242505 Al(KANIGA, K ) 02 December 2004 1-47, 50, 51 See formula I, examples, claims 1-47 US 4643987 A(NAGARAJAN, R ET AL ) 17 February 1987 1-47, 50, 51 See formula 1, examples 1-27, claims 1-24 US 7208471 B2(LEADBETTER, M R ) 24 April 2007 1-47, 50, 51 See formula I, II, examples, claims 1-5 Further documents are listed in the continuation of Box C See patent family annex * Special categories of cited documents "X" later document published after the international filing date or priority "A" document defining the general state of the art which is not considered date and not in conflict with the application but cited to understand to be of particular relevance the principle or theory underlying the invention "E" earlier application or patent but published on or after the international "X" document of particular relevance, the claimed invention cannot be filing date considered novel or cannot be considered to involve an inventive "L" document which may throw doubts on priority claim(s) or which is step when the document is taken alone cited t o establish the publication date of citation or other "Y" document of particular relevance, the claimed invention cannot be special reason (as specified) considered to involve an inventive step when the document is "O" document referring to an oral disclosure use, exhibition or other combined with one or more other such documents, such combination means being obvious to a person skilled in the art "P" document published prior to the international filing date but later "Si" document member of the same patent family than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report 22 JUNE 2009 (22 06 2009) 22 JUNE 2009 (22.06.2009) Name and mailing address of the ISA/KR Authorized officer Korean Intellectual Property Office Government Complex-Daej eon, 139 Seonsa-ro, Seo- KANG Young Jin gu, Daejeon 302-701, Republic of Korea Facsimile No 82-42-472-7140 Telephone No 82-42-481-8391 Form PCT/ISA/210 (second sheet) (July 2008) INTERNATIONAL SEARCH REPORT International application No PCT/US2008/085716 Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet) This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons 1 |\7| Claims Nos 4 9 because they relate to subject matter not required to be searched by this Authority, namely Claim 49 pertains to methods for treatment of the human or animal body by therapy, and thus relate to a subject matter which this international Searching Authority is not required, under Article 17(2)(a)(i) of the PCT and Rule 39 l(iv) of the Regulations under the PCT, to search 2 I I Claims Nos because they relate to parts of the international application that do not comply with the prescnbed requirements to such an extent that no meaningful international search can be earned out, specifically Claims Nos 48, 49 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a) Box No. Ill Observations where unity of invention is lacking (Continuation of item 3 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows 1 \~ \ As all required addtional search fees were timely paid by the applicant, this international search report covers all searchable claims 2 I I As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee 3 I I As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos No required additional search fees were timely paid by the applicant Consequently, this international search report is restncted to the invention first mentioned in the claims, it is covered by claims Nos Remark on Protest The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee I I The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation I I No protest accompanied the payment of additional search fees Form PCT/ISA/210 (continuation of first sheet (2)) (July 2008) INTERNATIONAL SEARCH REPORT International application No Information on patent family members PCTYUS2008/085716 Patent document Publication Patent family Publication cited in search report date member(s) date US 7074760 B2 11 07 2006 US 6906031 14.06.2005 US 7244705 17.07.2007 US 2002-0055464 A1 09.05.2002 US 2002-055464 A1 09.05.2002 US 2006-1947 16 A1 31.08.2006 US 6770621 B2 03.08.2004 US 6906031 B2 14 06 2005 US 2003-008812 A 1 09 0 1 2003 None US 2004-242505 A 1 02 12 2004 US 7521418 21.04.2009 US 4643987 A 17 02 1987 None US 7208471 B2 24 04 2007 US 6635618 2 1 10 2003 US 6872701 29.03.2005 US 6887976 03 05 2005 US 7008923 07.03.2006 US 7351691 01.04.2008 US 2002-0022590 A1 21.02.2002 US 2002-022590 A1 21.02.2002 US 2004-00639 16 A1 01.04.2004 US 2004-0639 16 A1 01.04.2004 US 2005-01649 16 A1 28.07.2005 US 2005-1649 16 A1 28 07 2005 US 2006-0063706 A1 23.03.2006 US 2006-063706 A1 23.03.2006 US 2007-00495 19 A1 01.03.2007 US 6635618 B2 21. 10.2003 US 6872701 B2 29.03.2005 US 6887976 B2 03.05.2005 US 7008923 B2 07.03.2006 Form PCT/ISA/210 (patent family annex) (July 2008)